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SYNOPSIS 
 
 
 
 
 
The nucleolar process of ribosome biogenesis is deregulated in many tumors, 
but has been disregarded in cancer research until recently. Mutations of ribosomal 
proteins have been shown to be causal for proliferative diseases and cancer. Key 
features of ribosome biogenesis, such as transcription and processing of ribosomal 
RNA (rRNA) are adaptable to the cell’s proliferation state. In fact, the structural and 
functional integrity of the human nucleolus is tightly connected to cell cycle 
regulation, cell growth, and proliferation. Ongoing ribosome biogenesis is a 
prerequisite for destabilization of the tumor suppressor p53, a key cell cycle 
regulator. Various kinds of stress, including chemotherapeutic drugs, inhibit 
ribosome biogenesis and stabilize p53. Thus, the nucleolus is a highly sensitive 
sensor of cellular stress.  
Previous work showed that the serine/threonine kinase-inhibitor Flavopiridol 
(FL) causes an efficient and specific block of ribosome biogenesis at the level of 47S 
rRNA processing and induces nucleolar stress. In the work described here, the 
molecular mechanism of FL-mediated 47S rRNA processing inhibition was analyzed. 
An RNAi screen identified the cyclin-dependent kinase 9 (Cdk9) as critical regulator 
of 47S rRNA processing. Cdk9 facilitates 47S rRNA processing by its function in 
RNA polymerase II (RNAP II) elongation. Inhibition of Cdk9-mediated RNAP II 
transcription depletes a set of small nucleolar RNAs (snoRNAs) critical for 47S rRNA 
processing. Precisely, Cdk9 activity is required for expression of rRNA processing-
regulating snoRNAs like SNORD3 (U3), SNORD14A (U14A), SNORA73A (U17a), 
SNORD22 (U22), and SNORD118 (U8). In particular, depletion of U8 snoRNA causes 
a specific processing defect of the 47S rRNA primary transcript in the 3’ external 
transcribed spacer (3’ETS) region. Defective 3’ETS processing, in turn, negatively 
feeds back on RNA polymerase I (RNAP I) transcription. The requirement of Cdk9 
for rRNA processing is conserved in yeast. Thus, Cdk9 links RNAP II transcription to 
rRNA processing by facilitating the biogenesis of critical snoRNAs.  
 
 
In a second project, I assessed the impact of 4-thiouridine (4sU) on rRNA 
synthesis. The uridine analog is frequently used in nascent RNA labelling 
experiments, but its biological activity has been poorly characterized, so far. My 
results show that 4sU treatment is sensed by the nucleolus. 4sU globally inhibits 
rRNA synthesis and triggers a nucleolar stress response.  
Taken together, the data presented in this thesis shed light on regulation of 
mammalian ribosome biogenesis. My work suggests that inhibition of Cdk9-
mediated snoRNA biogenesis is a promising approach to establish ribosome 
biogenesis as process of therapeutic relevance. The results may stimulate the 
development of small molecule inhibitors for non-genotoxic inhibition of ribosome 
biogenesis. 
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1. INTRODUCTION 
 
 
 
 
 
1.0 Opening remark 
Biology is the leading science of the 21st century. A large amount of 
exponentially growing knowledge has been accumulating within the last decades. 
Life sciences explore complex phenomena of life, covering all facets of biology from 
macroscopic analysis of populations and organisms to basic mechanisms and 
molecules at cellular and molecular level. Biomedical research not only contributes to 
the improved understanding of life, it also aims to transfer knowledge into clinical 
applications. There is a continuous medical need for the development of new 
therapeutic strategies. For example, > 10 % of deaths in high-income countries can be 
allocated to cancer. Increasing incidence rates underscore the importance to discover 
novel approaches to treat cancer (WHO, Fact sheet No. 310, 2011; RKI, Krebs in 
Deutschland, 2010).  
Ribosome biogenesis is a highly conserved process in the nucleolus of cells, 
which is tightly connected to cell growth and proliferation. Recent findings suggest 
that changes in ribosome biogenesis rate interfere with cell cycle regulation and have 
implications for tumor formation (Ruggero and Pandolfi, 2003). My thesis explores 
molecular principles of ribosome biogenesis regulation. Before introducing the theme 
in detail, key principles of the cell cycle for regulation of cell growth and 
proliferation will be presented. 
 
 
1.1 The cell cycle - basic principles and regulation 
A normal cell proceeds through repetitive, but limited phases of growth and 
division (Fig. 1A). The cell cycle can be divided into two distinct stages: interphase 
and M-phase. Quiescent cells that have stopped dividing can also rest in G0-phase. 
Interphase is further divided into G1-phase, S-phase, and G2-phase. In G1-phase, the 
cell’s metabolic activity is high, producing ribosomes and enzymes for DNA 
replication, the major event in S-phase. Another biosynthetic period in G2-phase is 
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required to prepare for the actual cell division in M-phase. M-phase is discriminated 
into mitosis (chromosomal segregation and nuclear division) and cytokinesis 
(division of the cytoplasm). Progression through the cell cycle is strictly driven by 
interplay of two classes of proteins: cyclins and cyclin-dependent kinases (Cdks), 
which form heterodimers in different combinations, with cyclins being the regulatory 
component and Cdks being the catalytical active component. In mammals, more than 
ten different Cdks and various cyclins have been discribed. While Cdks are 
constitutively expressed, expression of cyclins is phase-specific and, in some cases, 
Figure 1. The cell cycle: major checkpoints and cyclin expression. (A) The cell cycle comprises three 
major checkpoints: (1) the restriction point, which monitors G1- to S-phase transition, (2) the DNA damage 
checkpoint, which is required for G2- to M-phase transition, and (3) the metaphase/spindle checkpoint, which 
controls chromosomal separation. Relevant Cdk/cyclin complexes are indicated. (B) Cyclin expression during 
the cell cycle. Cyclin D, cyclin E, cyclin A, and cyclin B levels are plotted as a function of time (adapted from 
Bardin and Amon, 2001). (C) The restriction point. Transition from G1- to S-phase is under control of Cdk 
inhibitory proteins from the Cip/Kip (e.g. p21Cip) and INK4a (e.g. p16INK4a) families, which bind G1-phase 
Cdk4/6 and Cdk2. Upon growth stimulation, cyclin D is induced and activates Cdk4/6, which then activates 
E2F, cyclin E, and cyclin A. Active Cdk2 ensures progression to S-phase. Cdk2 inhibits p21Cip and Rb and 
induces S-phase genes. 
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mutually exclusive (Fig. 1B) (Grana et al., 1994; MacLachlan et al., 1995; Peng et al., 
1998; Rickert et al., 1996). Thus, distinct Cdk/cyclin complexes exist at distinct cell 
cycle phases, phosphorylating distinct downstream effectors, which regulate 
formation and activity of subsequent Cdk/cyclin complexes. The Cip/Kip and 
INK4a inhibitory proteins negatively regulate cell cycle progression by binding 
Cdk/cyclin complexes (Sherr and Roberts, 1999). These regulatory principles apply 
at three critical stages within the cell cycle, the checkpoints.  
The major checkpoint is called ‘restriction point’ and regulates transition from 
G1- to S-phase (Fig. 1C). This checkpoint is of particular importance, since transition 
into S-phase is irreversible. The cell cycle has to be completed after crossing the 
restriction point. INK4a proteins such as p16INK4a block the cell cycle by binding 
Cdk4/cyclin D complexes (Sherr, 1996). Once the cell receives a mitotic stimulus, 
cyclin D expression is induced. Cdk4 now preferentially binds cyclin D, forming an 
active complex. Cdk4/cyclin D phosphorylates and inactivates the Retinoblastoma 
protein (Rb), an inhibitor of the E2F transcription factor family (Morgan, 1997; Wang 
et al., 2001). Active E2F is released from phosphorylated Rb and induces expression 
of cyclin E and cyclin A (Hatakeyama and Weinberg, 1995; Weinberg, 1995; Dyson, 
1998). Cyclin E liberates Cdk2 from Cip/Kip family Cdk-inhibitors such as p21Cip. 
Active Cdk2/cyclin E further promotes transition from G1- to S-phase, since 
inhibition of p21Cip and Rb is manifested by Cdk2/cyclin E phosphorylation. 
Induction of cyclin A by E2F activates S-phase specific genes (Lees et al., 1993; 
DeGregori et al., 1995). Cyclin A induction is also self-stimulatory for formation of 
active Cdk2/cyclin A (Grana and Reddy, 1995; Pines, 1995; Sherr, 2000).  
Two further checkpoints need to be passed to complete the cell cycle. Entry to 
mitosis is regulated at the end of G2-phase, when replication is completed. This 
checkpoint is called DNA damage checkpoint. It ensures that no DNA damage, 
which frequently occurs in replication, is present before cell division. G2- to M-phase 
transition is regulated by the DNA damage sensitive CHK1 kinase, which both 
activates the Wee1 kinase and inactivates the Cdc25 phosphatase. Active Wee1 
phosphorylates the Cdk2/cyclin B complex and thereby restricts G2- to M-phase 
progression. After DNA repair has been completed, CHK1 kinase is inactive and can 
no longer activate Wee1 and inhibit Cdc25, respectively. Dephosphorylation of the 
Cdk2/cyclin A complex by Cdc25 enables cell cycle progression (Gould and Nurse, 
1989; Lundgren et al., 1991; Walworth et al., 1993; Cuddihy and O'Connell, 2003). The 
third major checkpoint is located in metaphase of mitosis. It ensures that all 
chromosomes are fully condensed before segregation in anaphase. Once 
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chromosomes are arranged properly at the mitotic plate, the anaphase-promoting 
complex (APC/C) is active. APC/C degrades securin, an inhibitor of separase, which 
subsequently cleaves cohesin, thereby releasing the chromosomes for segregation 
(Zachariae and Nasmyth, 1999). 
 
 
1.2 The nucleolus is embedded in the cell cycle 
Cell growth and proliferation is an enormous logistic task. The whole genome 
has to be copied and a huge amount of biosynthesis has to be performed to produce 
two daughter cells, which equal the mother cell. In fact, a proliferating cell consumes 
up to 80 % of its energy for the production of ribosomes (Thomas, 2000). Given that 
ribosome biogenesis is a prerequisite for cell growth and proliferation, it is evident 
that ribosome biogenesis and the cell cycle are co-regulated and influence each other. 
Before highlighting various connections between the nucleolus and cell cycle control, 
the structural und functional principles of ribosome biogenesis will be introduced.  
 
1.2.1 The nucleolus provides a structural frame for ribosome biogenesis 
Ribosome biogenesis takes place in the nucleolus (Brown and Gurdon, 1964; 
Miller and Beatty, 1969). The interphase nucleolus is a membrane-free sub-cellular 
component, which forms around nucleolar organizer regions (NORs) within the 
nucleus. NORs contain ribosomal DNA (rDNA) genes coding for ribosomal RNA 
(rRNA) (Perry, 1962; Ritossa and Spiegelmann, 1965). NORs are located on five 
acrocentric chromosomes 13, 14, 15, 21, and 22. Mammalian nucleoli can differ 
significantly in number and size; varying from 0.5 to 9 µm. Nucleoli can also fuse. 
Every mammalian nucleolus comprises a regular organization, the tripartite 
structure (Fig. 2). This organization consists of the fibrillar center (FC), the dense 
fibrillar component (DFC), and the granular component (GC). The nucleolar 
structure is largely defined by its composition and contrast in electron micoscropy 
(EM). The FC in the heart of the nucleolus is a fibrillar region with low contrast in 
EM. It is partially surrounded by the DFC, a region of compact texture and high 
contrast. FC and DFC are embedded in the GC, a granular structure establishing the 
bulk of a nucleolus. The mammalian nucleolus is surrounded with a ring of 
condensed heterochromatin, the perinucleolar chromatin. Interestingly, a nucleolar 
tripartite structure is not conserved throughout eukaryotes. In S. cerevisiae, for 
example, a bipartite structure consisting of fibrillar strands and granules has evolved. 
Yeast nucleoli lack perinucleolar chromatin (Hernandez-Verdun et al., 2010). 
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Evolution of the tripartite structure is provoked by the increasing size of intergenic 
 
non-transcribed rDNA spacers, necessitating a third nucleolar component to 
maintain a correct spatio-temporal regulation of ribosome biogenesis (Thiry and 
Lafontaine, 2005). Indeed, analysis of protein and RNA compositions show that 
distinct steps of ribosome biogenesis can be allocated to distinct nucleolar 
components. The FC contains non-transcribed rDNA, inactive RNAP I, and parts of 
the transcription machinery, such as upstream binding factor (UBF) or 
Topoisomerase II. Active rDNA transcription takes place at the interface between FC 
and DFC and produces large amounts of nascent, unprocessed rRNA precursors 
(pre-rRNAs). Processing and modification of pre-rRNAs mainly takes place in DFC, 
where small nucleolar ribonucleoprotein complexes (snoRNPs) concentrate. Most 
ribosomal proteins are present in GC, the major site of ribosome subunit assembly 
(Boisvert et al., 2007). 
 
1.2.2 The nucleolar structure is modulated by the cell cycle 
Nucleoli are dynamic structures and subject to strong morphological changes 
during the cell cycle. Assembly, maintenance and disassembly are closely linked to 
the transcriptional activity of RNAP I. Continuous synthesis of nascent pre-rRNA is 
the basis for the nucleolar structure and ribosome biogenesis during interphase 
(Dimario, 2004). In mitosis, however, nucleoli are disassembled. The Cdk1/cyclin B 
complex inactivates RNAP I transcription in mitosis (Heix et al., 1998). Most 
Figure 2. The nucleolar tripartite structure. (A) Light microscopy image of a human nucleus (U2OS cell, 
para-formaldehyde fixed). The nucleolus is visible as a dark-staining amorphic structure (red box). (B) 
Electron microscopy image of the human nucleolus (HeLa cell, glutaraldehyde and osmic acid fixed, 
contrasted with uranyl acetate). The nucleolar tripartite structure is visible. Star: fibrillar center (FC), Arrow: 
dense fibrillar component (DFC), GC: granular component. Scale bar: 0.5 !m (figure taken from Hernandez-
Verdun et al., 2010). (C) Scheme of the human nucleolus. The tripartite structure and its major nucleolar 
functions are illustrated. RNAP I: RNA polymerase I, UBF: upstream binding factor, snoRNP: small nucleolar 
ribonucleoprotein, NPM1: Nucleophosmin. 
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components of the RNAP I transcription machinery remain associated with rDNA 
during mitosis, whereas nucleolar processing components and partially processed 
pre-rRNAs translocate from the NOR to the cytoplasm or localize in the 
perichromosomal region (PR) (Roussel et al., 1996; Gautier, 1994; Leung et al., 2004). 
Cdk1/cyclin B levels decrease during telophase and early G1-phase, which 
reactivates RNAP I transcription and triggers nucleolar reassembly at the end of 
mitosis (Roussel et al., 1996) (Fig. 3). Nucleolar processing components and partially 
processed pre-rRNAs reassemble themselves in prenucleolar bodies (PNBs), which 
concentrate and release nucleolar components to nascent nucleoli in a defined order 
(Savino et al., 2001). Thus, the nucleolus is a cell cycle-dependent structure and 
‘formed by the act of building a ribosome’ (Mélèse and Xue, 1995). 
 
1.2.3 The nucleolus influences cell cycle progression 
The nucleolus sequesters a number of cell cycle regulating factors during 
interphase. Nucleolar sequestration prevents them from being active throughout the 
entire cell cycle. Human telomerase reverse transcriptase (hTERT) is sequestered in 
the nucleous by nucleolin. hTERT is released from nucleolin at late stages of S-phase 
to catalyze telomere replication (Wong et al., 2002; Khurts et al., 2004). The protein 
phosphatase 1 gamma isoform (PP1!) is also concentrated in nucleoli during 
interphase. PP1! is released from the disassembling nucleolus to the cytoplasm at the 
beginning of mitosis. PP1! binds mitotic chromosomes in anaphase to control 
chromosome condensation (Trinkle-Mulcahy et al., 2006; Vagnarelli et al., 2006; 
Trinkle-Mulcahy and Lamond, 2006). Similarly, Cdc14, a protein phosphatase crucial 
for promoting mitotic exit, is anchored in the nucleolus. Cdc14 binds the nucleolar 
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factor Net1 until onset of anaphase. Binding to Net1 prevents an uncoordinated 
mitotic exit (Visintin et al., 1998; Shou et al., 1999). In anaphase, Net1 is 
phosphorylated by the Cdk1/cyclin B complex and looses its affinity to Cdc14, which 
is now able to dissolve chromosomal linkages by promoting cohesin cleavage 
(Azzam et al., 2004; D’Amours et al., 2004). Depletion of ribosomal processing factors 
Nop15 or Rrp14 causes a cytokinesis defect and a mislocalization of the mitotic 
spindle followed by a mitotic arrest (Oeffinger and Tollervey, 2003; Oeffinger et al., 
2007). The examples characterize the interphase nucleolus as a storage domain, 
which is dissolved in mitosis to allow the coordinated release of critical factors that 
regulate cell cycle progression. 
 
 
1.3 Ribosome biogenesis at the molecular level 
Synthesis of ribosomes is the major function of the nucleolus. Nobel prize 
laureate Dr. Barbara McClintock connected the nucleolus with gene activity already 
in 1934. It took many decades until the understanding of ribosome biogenesis has 
evolved into one of the most complex processes of life. Ribosome biogenesis is highly 
coordinated and involves all three RNA polymerases. rRNA is synthesized, 
processed, modified, and assembled into ribosomal subunits. Mammalian 80S 
ribosomes consist of four rRNAs (28S, 18S, 5.8S rRNA transcribed by RNAP I, and 5S 
rRNA transcribed by RNAP III) and 79 ribosomal proteins (RNAP II transcripts) 
(Warner, 1999). The multiple steps of ribosome biogenesis are discussed next. 
 
Figure 3. Scheme of nucleolar reassembly in early G1-phase. The nucleolus remains disassembled until 
the end of telophase, when RNAP I transcription is reinitiated in nucleolar organizing regions (NORs) and the 
chromatin is still condensed (dark grey area). Mitotic chromatin decondenses in early G1a-phase (light grey 
area), the nucleus is assembled (broken line), numerous perinucleolar bodies (PNBs) form (dark foci) and the 
transcriptional active NORs recruit processing factors to the dense fibrillar component (DFC) (green). Transfer 
of processing proteins from PNBs to the DFC is almost completed in early G1b-phase and NORs regroup into 
nucleoli. Human nucleolar reassembly takes about two hours (adapted from Hernandez-Verdun et al., 2010). 
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1.3.1 RNAP I transcription 
rRNA transcription initiates ribosome biogenesis. Although rDNA comprises 
only 0.4 % of the human genome, the fraction of rRNA within the transcriptome can 
be up to 90 %, implicating that rDNA genes are heavily transcribed (Rabani et al., 
2011). In total, about 400 rDNA tandem repeats ensure continuous biogenesis of one 
to two million ribosomes per cell (Prieto and McStay, 2008; Drygin et al., 2010). Many 
rDNA repeats are transcriptional inactive, which allows adaption to changing 
growth conditions and genome maintenance (Birch and Zomerdijk, 2008; 
Stefanovsky and Moss, 2006; Ide et al., 2010). Each rDNA repeat has a size of 
approximately 44 kilobases (kb), composed of a 14 kb coding region and a 30 kb long 
intergenic spacer sequence. Transcription of rDNA repeats produces a polycistronic 
47S rRNA primary transcript, which contains 18S, 5.8S, and 28S rRNA and is 
performed by RNAP I, a 14-subunit enzyme with high structural similarity to RNAP 
II and III (Fatica and Tollervey, 2002; Kuhn et al., 2007; Werner et al., 2009).  
Initiation is the critical and most regulated step in RNAP I transcription (Fig. 
4, upper panel). Initiation of mammalian RNAP I transcription requires four essential 
transcription factors: transcription initiation factor 1A (TIF-1A), the selectivity factor 
1 (SL1) complex, upstream binding factor (UBF), and transcription termination factor 
1 (TTF-1). The latter also terminates RNAP I transcription. TIF-1A is associated with 
RNAP I and is required to render RNAP I competent for initiation (Peyroche et al., 
2000). The SL1 complex consists of multiple subunits, including TATA-binding 
protein (TBP), and binds the core promoter. The SL1 complex is crucial for start site 
selection (Russel and Zomerdijk, 2006). UBF binds the upstream control element 
(UCE) as homodimer and facilitates RNAP I recruitment and promoter escape. UBF 
also stabilizes SL1 binding (Jantzen et al., 1990; Panov et al., 2006; Stefanovsky et al., 
2006; Kuhn and Grummt, 1992). RNAP I is recruited to the promoter by synergistic 
binding of the SL1 complex and UBF. Recently, it was shown that actively 
transcribed rDNA repeats contain nucleosomes and remodelling factors, which 
regulate chromatin accessibility (Jones et al., 2007). Antisense transcription of rDNA 
produces a short non-coding RNA, which binds the promoter to recruit enzymes for 
epigenetic modification and thereby regulate initiation (Schmitz et al., 2010).  
 
1.3.2 rRNA processing and maturation 
RNAP I synthesizes a nascent 47S rRNA primary transcript, which is bound 
co-transcriptional by large and small ribosomal L- and S-proteins and processing 
factors to form a large and highly dynamic ribonucleoprotein complex, the 90S pre-
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ribosome. Several rRNA synthesis steps happen simultaneously within the 90S pre-
ribosome. More than 200 factors such as small nucleolar RNAs (snoRNAs), RNA 
helicases, nucleases, GTPases, and export factors are required to assemble, process, 
and mature ribosomes by continuous association and dissociation from immature 
ribosomes (Staley and Woolford, 2009). The 90S pre-ribosome is the stage of 47S 
rRNA modification and processing. Distinct sites of the nascent pre-rRNA precursor 
get methylated at the 2’ oxygen of the ribose (2’-O-Met) and a subset of uridines is 
converted to pseudouridines (") (Cavaillé et al., 1996; Ganot et al., 1997; Weinstein 
and Steitz, 1999; Kiss, 2002). Both modifications are introduced by roughly 70 
snoRNPs (Balakin et al., 1996; Tran et al., 2003). Each snoRNP contains one 
modifying enzyme (Fibrillarin for 2’-O-Met, Dyskerin for "), one snoRNA, and 
additional stabilizing proteins. SnoRNAs can be divided into two families according 
to structural similarities, conserved sequence elements, and associated proteins. Box 
C/D snoRNAs guide rRNA methylation and form a box C/D snoRNP. Box H/ACA 
snoRNAs guide rRNA pseudouridylation and form a box H/ACA snoRNP (Kiss, 
2002; Decatur and Fournier, 2003). Extensive rRNA modification occurs at catalytical 
active rRNA regions within the decoding and peptidyl transferase centers of the 
ribosome (Bakin et al., 1994). Modifications are guided by complementary base 
pairing of snoRNAs and facilitate rRNA folding to stabilize nascent pre-rRNA. 
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SnoRNPs bind the pre-rRNA modification region surrounding the nucleotide to be 
modified (Kiss-László et al., 1996; Bachellerie et al., 2002).  
Little is known about enzymes that catalyze mammalian rRNA processing. 
Endo- and exonucleases cleave and trim external and internal transcribed spacers 
within polycistronic 47S rRNA (Kos and Tollervey, 2005; Venema et al., 1997). 47S 
rRNA processing is characterized by a cleavage cascade and stepwise production of 
intermediate rRNA forms, which finally mature to 18S, 5.8S, and 28S rRNA 
Figure 4. Transcription and processing of mammalian ribosomal RNA. RNAP I transcription occurs on 
tandem rDNA repeats. Each rDNA repeat contains a promoter region, a transcription start site (+1), a 
polycistronic transcription unit, and a termination site (T). RNAP I initiation is facilitated by four general 
transcription factors: TTF-1, UBF, the SL1 complex, and TIF-1A. The polycistronic transcription unit encodes a 
47S precursor rRNA, which contains a 5’ external transcribed spacer (5’ETS), 18S rRNA, an internal 
transcribed spacer 1 (ITS-1), 5.8S rRNA, an internal transcribed spacer 2 (ITS-2), 28S rRNA, and a 3’ external 
transcribed spacer (3’ETS). The 47S rRNA primary transcript undergoes co-transcriptional rRNA modifications 
(methylation, pseudouridylation) and a cascade of endonucleolytic cleavages (scissors) and exonucleolytic 
degradation steps (trimming). UCE: upstream control element, IGS: intergenic spacer (adapted from Mullineux 
and Lafontaine, 2012). 
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(Hadjiolova et al., 1993) (Fig. 4, lower panel). In yeast, there are two independent and 
spatially separated processing machineries. While 40S maturation is facilitated by the 
small subunit processome (SSU), 60S maturation requires different processing and 
assembly factors (Dragon et al., 2002; Grandi et al., 2002). The yeast 35S rRNA 
primary transcript is initially cut by the t-UTP-complex. The t-UTP-complex contains 
SNORD3 (U3) snoRNA, which catalyzes 5’ETS processing of the primary transcript 
and directs correct folding of cleaved rRNA (Gallagher et al., 2004; Gerbi et al., 2001). 
3’ETS processing of 35S rRNA is performed by the Rnt1 endonuclease. Rnt1 cleavage 
produces a 27S rRNA intermediate, which is then cleaved by RNase MRP in ITS-1 
and trimmed by 3’-5’ exonuclease Rex1. Additional trimming of premature 25S 
rRNA by 5’-3’ exonucleases Xrn1/Rat1 produces mature 25S rRNA. Rex1 is also 
involved in trimming of premature 5.8S rRNA (Fatica and Tollervey, 2002; Peculis 
and Steitz, 1993). Some processing factors in yeast have homologs in higher 
eukaryotes. For example, human ribosomal processing factors Pes1, Bop1, and 
WDR12 form a trimeric complex, PeBoW, which is essential for ITS-2 processing of 
intermediate 32S rRNA into mature 28S rRNA (Lapik et al., 2004; Hölzel et al., 2005; 
Grimm et al., 2006; Hölzel et al., 2007; Rohrmoser et al., 2007). Nucleophosmin 
(NPM1) and Nucleostemin (NST) also modulate ITS-2 processing (Haindl et al., 2008; 
Itahana et al., 2003; Romanova et al., 2009).  
On its transport to the nucleoplasm, the 90S pre-ribosome splits into pre-60S 
and pre-40S particles, which further mature in the nucleoplasm. 60S and 40S 
ribosomal subunits are exported to the cytoplasm and form mature 80S ribosomes for 
translation of messenger RNAs (mRNAs) (Gadal et al., 2001; Thomas and Kutay, 
2003; Tschocher and Hurt, 2003). Importantly, recent findings suggest that ribosomes 
are more than just machines that translate mRNA. Ribosomal protein composition 
affects gene regulation and tissue development. For example, a mutation in 
ribosomal protein L38 reduces the translational efficacy for Hox factors in a tissue 
specific manner (Kondrashov et al., 2011). Great heterogeneity in ribosomal protein 
expression suggests the existence of ribosomes, which are specialized for translation 
of mRNAs in a tissue specific manner.  
 
1.3.3 The multifunctional nucleolus 
The nucleolus is involved in processing and maturation of various RNAs and 
RNPs. First, 5S rRNA, a product of RNAP III transcription, enters the nucleolus in 
complex with ribosomal protein L5 for maturation and incorporation into the 
ribosome (Steitz et al., 1988). The transfer RNA (tRNA) processing component RNase 
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P localizes in the nucleolus, suggesting a role for tRNA splicing (Bertrand et al., 
1998). Adenosine deaminase ADRA1 is active in the nucleolus, which assigns RNA 
editing as a nucleolar function (Vitali et al., 2005). The nucleolus seems also to be 
involved in RNA interference (RNAi). Endogenous short interfering RNAs (siRNAs) 
co-localize in the nucleolus together with components of the RNAi processing 
machinery (Pontes et al., 2006). The nucleolus is also required for assembly and 
maturation of various RNPs, such as the U6 sliceosomal small nuclear RNP, 
telomerase, or the signal recognition particle (SRP), thereby contributing to splicing, 
telomere replication, and peptide sorting (Ganot et al., 1999; Mitchell et al., 1999; 
Jacobson and Pederson, 1998; Politz et al., 2000). In summary, the nucleolus is a 
multifunctional compartment. 
 
1.3.4 Surveillance of ribosome biogenesis 
Nucleolar ribosome biogenesis is a complex, non-linear, and error-prone 
process. Up to 80 % of pre-rRNAs in the cell are produced incorrectly. Defective pre-
rRNAs need to be eliminated to ensure biogenesis of high quality ribosomes. A 
robust surveillance mechanism is required to prevent production of misassembled 
ribosomes with poor translational capacity. Defective pre-rRNAs are 3’-
polyadenylated by interaction with accessory factors like the TRAMP complex, the 
Nrd1 complex, or the Ski7 complex (LaCava et al., 2005; Orban and Izaurralde, 2005). 
Polyadenylation recruits the exosome and triggers degradation of defective pre-
rRNA. The exosome is a 400 kDa multi-enzyme complex with 3’-5’ exonuclease 
activity. The exosome consists of nine core subunits and one catalytical active 
subunit (Kuai et al. 2004; Allmang et al. 1999). Recently, it was shown that three 
distinct exosome isoforms, differing in their cellular localization and 3’-5’ 
exonuclease subunit, exist in mammalian cells. While hRrp6 is the catalytic subunit 
of nucleolar exosomes, hDIS3 and hDIS3L are present in nucleoplasmatic and 
cytoplasmic exosomes, respectively. The putative RNA helicase hMtr4 is also 
required for nuclear exosome activity; it unwinds defective pre-rRNAs (Tomecki et 
al., 2010; Staals et al., 2010; Lubas et al., 2011). The exosome is part of the major 
quality control pathway for rRNAs, but it also facilitates degradation of defective or 
dispensable mRNAs and maturation of other non-coding RNAs such as snoRNAs, 
snRNAs, and tRNAs (Anderson and Parker, 1998; Mukherjee et al., 2002; Wyers et 
al., 2005). 
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1.4 RNAP II transcription 
A basic overview of RNAP II transcription and its regulation is described next, 
as the transcriptional activity of RNAP II will be a key subject of this thesis. RNAP II 
transcribes mRNAs for 79 ribosomal proteins and > 200 processing and synthesis 
factors for ribosomes including snoRNAs. Eukaryotic RNAP II consists of 12 
subunits (Rpb1-12) (Cramer, 2004). The 10-subunit core complex shows high 
conservation with RNAP I and III. RNAP II has evolved two additional subunits, 
Rpb4 and Rpb7, which are potential paralogs to RNAP I subunits (Edwards et al., 
1991; Cramer, 2002). The largest subunit of RNAP II (Rpb1) harbors a repetitive 
carboxy-terminal domain (CTD). The RNAP II CTD is flexible and locates in close 
proximity to the RNA exit pore and nascent mRNA (Noble et al., 2005; Armache et 
al., 2005). The CTD is unique to RNAP II and comprises an evolutionary conserved, 
tandemly arranged repetitive consensus amino acid sequence, the Y1S2P3T4S5P6S7 
heptad. The mammalian CTD is composed of 52 heptad repeats (Chapman et al., 
2008).  
RNAP II transcription can be roughly divided into three distinct stages: 
initiation, elongation, and termination. These stages are repeated in a transcription 
cycle (Fig. 5). Interestingly, the phosphorylation patterns of the CTD vary upon 
progression through the transcription cycle. RNAP II initiation is orchestrated by the 
interplay of three distinct classes of regulatory factors. First, sequence-specific 
transactivators bind enhancer sequences. Second, transcriptional co-activators such 
as the Mediator complex or chromatin remodellers and histone modifying enzymes 
are recruited, making the promoter accessible for the third class of regulatory factors, 
the general transcription factors (GTFs) (Hahn, 2004). Six GTFs (TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF, and TFIIH) sequentially bind the promoter and recruit RNAP II to form 
the pre-initiation complex (PIC) (Orphanides et al., 1996; Ptashne, 1986). Prior to 
recruitment, RNAP II CTD is phosphorylated at position serine-5 by the Cdk8/cyclin 
C complex, a cofactor of the Mediator. Cdk8 prevents premature PIC formation, 
which only forms after dephosphorylation of serine-5 by the Fcp1 phosphatase 
(Hengartner et al., 1998; Kamenski et al., 2004). Several critical events are required in 
order to release RNAP II from the promoter and the transit into elongation. In brief, 
XPB/D helicase activity in TFIIH melts 11-15 base pairs of DNA to make the 
template accessible for transcription. Cdk7 kinase activity in TFIIH re-
phosphorylates the CTD at serine-5 (Hengartner et al., 1998). Serine-5 
phosphorylation triggers a partial PIC disassembly and allows RNAP II to escape 
from the promoter, entering a short critical phase of instable abortive initiation, 
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which is immediately stabilized by the increasing length of the nascent transcript (Pal 
and Luse, 2003; Kireeva et al., 2000). Promoter proximal pausing of RNAP II enables 
capping and stabilizes nascent mRNA. RNAP II CTD phosphorylation at serine-5 
was also shown to be required for recruitment of the capping enzyme (Yamaguchi et 
al., 1999; Wada et al., 1998; Pei and Shuman, 2002).  
RNAP II is now competent for productive elongation, but is still retracted by 
negative transcription elongation factor (NELF) and the Spt4/5 heterodimer. 
Productive elongation is stimulated by the positive transcription elongation factor b 
Figure 5. The RNAP II transcription cycle. (1) RNAP II recruitment and PIC formation. RNAP II forms a pre-
initiation complex (PIC) together with general transcription factors (GTFs) and the Mediator complex. (2) 
Promoter initiation and escape. Cdk7 phosphorylates the RNAP II carboxy-terminal domain (CTD) at serine-5 
and -7, which destabilizes the PIC and initiates transcription. RNAP II initial transcription is abortive and 
pauses before elongation. The nascent pre-mRNA is capped. (3) RNAP II elongation. Cdk9 phosphorylates 
the RNAP II CTD at serine-2 and -5 and triggers transition from promoter proximal pausing to elongation. (4) 
Co-transcriptional pre-mRNA splicing occurs at hyperphosphorylated CTD, which recruits splicing factors and 
is crucial for small nuclear (sn)RNA transcription. (5) Termination of RNAP II transcription. RNAP II reaches a 
poly-A-site and RNAP II phosphatase Scp1 dephosphorylates the CTD at position serine-5. Pre-mRNA is 
cleaved and RNAP II dissociates from the template. (6) RNAP II recycling. CTD phosphatases Fcp1 and 
RPAP2 dephosphorylate the CTD at positions serine-2 and -7. Hypophosphorylated RNAP II dissociates from 
the DNA, forming an inactive pool. 
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(pTEFb), which consists of Cdk9 and cyclin T1 (Marshall et al., 1996; Price, 2000). 
pTEFb phosphorylates both NELF, Spt4/5, and the RNAP II CTD at positions serine-
2 and -5. NELF dissociates from RNAP II after pTEFb phosphorylation (Fujinaga et 
al., 2004; Yamada et al., 2006; Cho et al., 2001; Marshall et al. 1996; Andrulis et al., 
2000; Czudnochowski et al., 2012). Thus, phosphorylation of the CTD at position 
serine-2 is a hallmark for elongating RNAP II. A number of additional factors, such 
as TFIIF or the Elongator complex promote RNAP II elongation by chromatin 
remodelling (Cheng and Price, 2007; Close et al., 2006). Splicing of precursor-mRNAs 
(pre-mRNAs) is a second important co-transcriptional event. It is not entirely clear, 
whether co-transcriptional splicing requires active RNAP II elongation or is linked to 
the CTD solely as a mechanical binding platform, independent of mRNA synthesis 
(Kornblihtt, 2004). The splicing machinery can bind nascent mRNA either directly or 
via the CTD (Moore et al., 2006; de la Mata and Kornblihtt, 2006). Occasionally 
during elongation, RNAP II backtracks in the gene. Backtracking involves TFIIS and 
may increase RNAP II transcriptional fidelity (Cheung and Cramer, 2011). RNAP II 
CTD is also phosphorylated at position serine-7. The CTD serine-7 phosphorylation 
is introduced by Cdk7 (Chapman et al., 2007; Akhtar et al., 2009). It has been shown 
that serine-7 phosphorylation recruits the Integrator complex and is specifically 
required for small nuclear RNA (snRNA) transcription (Baillat et al., 2005; Egloff et 
al., 2007).  
RNAP II termination requires a poly-A-site, cleavage and processing factors 
like Pcf1, Sen1, Nab3, or Nrd1 (Zaret and Sherman, 1982; Birse et al., 1998; Steinmetz 
et al., 2001). CTD phosphorylations are sequentially removed by phosphatases like 
Scp1, Fcp1, and RPAP2 (Proudfoot, 1997; Vasiljeva et al., 2008; Yeo et al., 2005; Egloff 
et al., 2012). Removal of c-Abl-mediated CTD phosphorylation at position tyrosine-1 
is required for the interaction of the RNAP II CTD with termination factors (Mayer et 
al., 2012). There are two alternative models for RNAP II termination: the allosteric 
model, in which RNAP II undergoes a conformational change at the poly-A-site, 
leading to loss of processivity and gradual termination (Greenblatt et al., 1993). In the 
torpedo model, RNAP II is targeted by the 5’-3’ exonuclease Rat1 (torpedo), which 
attacks the 5’ end of the nascent transcript after endonucleolytic cleavage (Conelly 
and Manley, 1988; Kim et al., 2004). Rat1 catches up to RNAP II and triggers its 
release from the gene. Interestingly, RNAP II termination is coupled to 3’ end 
processing by interdependent recruitment between Rat1 and 3’ end processing 
factors like Pcf1 (Luo et al., 2006). Once terminated, RNAP II is subsequently 
available for another round of transcription.  
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1.5 SnoRNA biogenesis and pre-mRNA splicing are coupled events 
Rat1 not only is required for rRNA synthesis and RNAP II termination, it also 
contributes to snoRNA biogenesis (Petfalski et al., 1998). In higher eukaryotes, most 
snoRNAs are co-transcribed within pre-mRNA and released from excised and 
debranched introns by exonucleolytic trimming (Kiss and Filipowicz, 1995; Richard 
and Kiss, 2006) (Fig. 6). The mature mRNAs of these pre-mRNAs often encode for 
proteins involved in ribosome biogenesis (Kiss, 2002). For example, box C/D 
snoRNA U14A is encoded in the Hsc70 pre-mRNA (Liu and Maxwell, 1990; Watkins 
et al., 1996). Four snoRNA-stabilizing proteins associate with the intronic pre-
snoRNA sequence during pre-mRNA splicing (15.5kD, Nop56, Nop58, and 
Fibrillarin with box C/D snoRNAs; Nop10, Nhp2, Dyskerin (DKC1), and Gar1 with 
box H/ACA snoRNAs) (Hirose et al., 2003; Richard and Kiss, 2006; Darzacq et al., 
2006). Assembly of pre-snoRNP complexes protects the pre-snoRNA from 
exonucleolytic degradation. Box C/D snoRNPs require the Hsp90 chaperone and its 
co-chaperone, the R2TP (Rvb1, Rvb2, Tah1, and Pih1)/Prefoldin-like (hereinafter 
R2TP) complex for correct folding, assembly, and stabilization. Box H/ACA snoRNP 
assembly also requires the Naf1 assembly factor (Hoareau-Aveilla et al., 2006; 
Ballarino et al., 2005). Thus, RNAP II transcription and co-transcriptional splicing 
actively promote snoRNA biogenesis. 
 
 
1.6 Ribosome biogenesis in context of cancer 
Ribosome biogenesis is upregulated upon growth factor stimulation and 
downregulated upon nutrient starvation (Drygin et al., 2010). In cancer cells, 
ribosome synthesis is altered in conditions of derailed growth control. Nucleolar 
morphology has been used as a diagnostic marker for the proliferative state of cancer 
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Figure 6. SnoRNP assembly is coupled with pre-mRNA transcription and splicing. (A) Assembly of box 
C/D small nucleolar ribonucleoproteins (snoRNPs) is dependent on the Hsp90/R2TP chaperone and active 
splicing. Hsp90/R2TP facilitates assembly of RNAP II and folding and assembly of box C/D core proteins 
15.5kD, Fibrillarin (Fib), Nop58, and Nop56. Most box C/D snoRNAs are located about 50 nucleotides (nts) 
upstream of the branch point (BP) and are processed in a splicing-dependent manner. SnoRNPs assemble by 
successive binding of 15.5kD, Fib, Nop58, and Nop56. 15.5kD binds before splicing and debranching. Fib and 
Nop58 bind before processing. Binding of Nop56 completes snoRNP assembly. (B) Transcription-dependent 
assembly of box H/ACA snoRNPs. Assembly of pre-snoRNPs occurs co-transcriptionally. Nucleolar assembly 
factor 1 (Naf1) interacts with the RNAP II carboxy terminal domain (CTD) and facilitates recruitment of box 
H/ACA core proteins Dyskerin (DKC1), Nop10, and Nhp2 to nascent snoRNA. Gar1 core protein binds the 
pre-snoRNP probably after splicing and debranching. Note that a fraction of box C/D snoRNPs, which have 
suboptimal intronic positions and carry stem-loop structures, might follow a transcription-dependent pathway 
similar to box H/ACA snoRNP assembly (Hirose et al., 2003) (adapted from Richard and Kiss, 2006). 
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cells > 100 years ago (Pianese, 1896). In fact, an increase in nucleolar size correlates 
with increased ribosome biogenesis to meet high demands of protein synthesis for 
elevated tumor growth (Derenzini et al., 1998). Next, key principles of tumor 
formation are introduced before deregulation of ribosome biogenesis in cancer will 
be reviewed.  
Cancer is a proliferative disease, defined as a neoplasm forming malignant 
tumors. Cancer cells have escaped the cellular mechanisms that restrict cell growth 
and proliferation. They are resistant to programmed cell death and have the ability to 
invade other tissues, form metastases, and spread around the body. Malignancy is 
achieved by cellular transformation, a multi-causal process of stepwise accumulation 
of somatic mutations. Which mutations drive transformation? Key regulators of the 
cell cycle and cell growth are frequently mutated in tumors (Croce, 2008). Two types 
of genes influence cell growth: proto-oncogenes and tumor suppressor genes. Proto-
oncogenes can become hyperactive oncogenes by dominant gain of function 
mutations; tumor suppressor genes drive transformation by recessive loss of function 
mutations. Proto-oncogenes support growth by driving the cell cycle or stimulating 
signalling pathways. Typical examples of proto-oncogenes encode transcription 
factors such as c-Myc, kinases involved in signal transduction (e.g. Src, Raf, ERK or 
Abl), or cell cycle regulators like E2F. Tumor suppressors restrict growth. They 
decelerate cell cycle progression and are pro-apoptotic. One of the most important 
tumor suppressors is the p53 protein. p53 is regarded as the guardian of the genome, 
which senses DNA damage by induction of G1-arrest or apoptosis (Carson and Lois, 
1995; Levine 1997). The Rb protein is another major tumor suppressor that inhibits 
E2F at the restriction point (Sherr, 2000). Importantly, ribosome biogenesis is 
regulated by prominent proto-oncogenes and tumor suppressor genes, which are 
frequently mutated in cancer (Table 1). 
 
Table 1. Cancer genes and ribosome biogenesis regulation. Mutations in major proto-oncogenes and 
tumor suppressor genes deregulate RNAP I transcription, rRNA processing, and translation. 
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1.6.1 Deregulation of RNAP I transcription in cancer 
RNAP I transcription initiation is strongly regulated by UBF and TIF-1A. High 
levels of hyperphosphorylated UBF and TIF-1A are present in growth favourable 
conditions, driving RNAP I transcription, ribosome biogenesis, and proliferation. 
Three serine/threonine kinases achieve hyperphosphorylation of UBF and TIF-1A: 
casein kinase II (CK II), S6 kinase (S6K) and extracellular signal-regulated kinase 
(ERK) (Voit et al., 1992; Stefanovsky et al., 2001; Zhao et al., 2003; Panova et al., 2006). 
Consequently, UBF is frequently upregulated in cancer, but downregulated and 
hypophosphorylated in quiescent cells (Drygin et al., 2010). CK II, ERK, and the 
various components of the receptor tyrosine kinase signalling pathway (e.g. Ras, Raf, 
or MEK) are also frequently mutated in human cancer cells, allowing self-stimulatory 
ribosome biogenesis induction independent from extracellular growth factors 
(Huang et al., 2002; Guerra and Issinger, 2008; McCubrey et al., 2007). c-Myc binds 
the RNAP I promoter to stimulate rRNA transcription (Arabi et al., 2005; Grandori et 
al., 2005). c-Myc also induces UBF and is upregulated in many tumors (Poortinga et 
al., 2004; Meyer and Penn, 2008). p53 represses rRNA transcription in vitro by 
inhibiting both the SL1 complex and UBF, which prevents PIC formation (Zhai and 
Comai, 2000). Alterations in the p53 status are found in > 50 % of all tumors (Sigal 
and Rotter, 2000; Toledo and Wahl, 2006). Rb binds UBF and thereby diminishes 
rRNA transcription (Cavanaugh et al., 1995; Voit et al., 1997). Consequently, loss of 
function mutations in Rb favour ribosome biogenesis. Taken together, RNAP I 
initiation is strongly influenced by major proto-oncogenes and tumor suppressor 
genes. 
 
1.6.2 Deregulation of rRNA processing and protein synthesis in cancer 
c-Myc also drives ribosome biogenesis by induction of various genes required 
for rRNA processing, ribosomal maturation, and translation (Boon et al., 2001; 
Schlosser et. al., 2003). The tumor suppressor PTEN negatively regulates ribosome 
biogenesis. PTEN phosphatase downregulates phosphatidylinositol 3-kinase (PI3K) 
signalling. PI3K activates the mammalian Target of Rapamycin (mTOR) kinase, 
which then activates S6-kinase (S6K) and drives translation initiation. Active S6K 
phosphorylates ribosomal protein S6, which enhances translation of 5’-terminal 
oligopyrimidine tract mRNAs (5’TOP mRNAs) coding for transcription factors, 
which, in turn, enhance expression of ribosomal processing factors in a self-
stimularory manner (Thomas et al., 1979; Terada et al., 1994; Ruggero and Pandolfi, 
2003). Mutations in PTEN and S6K can trigger constitutive PI3K signalling, which 
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stimulates ribosome biogenesis and tumorigenesis (Salmena et al., 2008; Yin and 
Shen, 2008). Overexpression of p14ARF protein was shown to inhibit rRNA processing 
(Sugimoto, et al., 2003). In line with that, rRNA processing is enhanced in p19ARF-
deficient mice (Apicelli et al., 2008). Depletion of NPM1 also inhibits rRNA 
processing (Itahana et al., 2003). Not surprisingly, PTEN, p14ARF, and NPM1 are 
frequently mutated in tumors (Ruggero and Pandolfi, 2003). Taken together, 
numerous examples demonstrate various options of ribosome biogenesis regulation 
to be altered in cancer. With no doubt, deregulation of ribosome biogenesis occurs in 
tumor cells and is crucial to maintain increased proliferation rates (White, 2005). 
From a therapeutic point of view, it would be desirable to develop strategies to 
downregulate ribosome biogenesis and restrict tumor growth. How could ribosome 
biogenesis be linked with cancer therapy? 
 
 
1.7 The nucleolus as stress sensor 
There is increasing evidence that the nucleolus is a sensitive stress sensor. The 
nucleolar stress response is directly connected to p53 levels (Fig. 7). In unstressed 
conditions, the nucleolar structure remains intact, ribosome biogenesis is functional 
and p53 levels are maintained low by Hdm2, an E3-ubiquitin ligase that 
continuously binds p53, ubiquitinates it, and targets it for proteasomal degradation 
(Stommel et al., 1999; Ljungman, 2000; Xirodimas et al., 2001). In fact, the nucleolus 
directly regulates p53 levels, since it is the site of p53 ubiquitination. p53 requires a 
transit through a structural and functional intact nucleolus to be degraded (Boyd et 
al., 2011). In case of nucleolar stress, however, the nucleolus disintegrates, which is 
accompanied by a translocation of various nucleolar proteins to the nucleoplasm 
(Rubbi and Milner, 2003; Hernandez-Verdun et al., 2010). Subsequently, Hdm2 is 
bound and inactivated by translocated ribosomal proteins, most prominently by L5, 
L11, and L23 (Lohrum et al., 2003; Dai et al., 2004a; Bhat et al., 2004; Dai et al., 2004b). 
The ribosomal protein L11 was found to be crucial for p53 induction. Similarly, other 
nucleolar factors such as p14ARF, NPM1, or NST are capable of inactivating HDM2 
and thereby stabilizing p53 (Tao and Levine, 1999; Kurki et al., 2004; Tsai and 
McKay, 2005). Unincorporated L26 protein can promote p53 translation (Takagi et al., 
2005; Chen and Kastan, 2010). Various forms of nucleolar stress, including heat, 
hypoxia, or UBF depletion cause nucleolar disruption and thereby stabilize p53 
(Rubbi and Milner, 2003). Consequently, functional ribosome biogenesis is a 
prerequisite for low levels of p53. The interplay between p53 and the nucleolus also 
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explains cell cycle-dependent variations in p53 levels, which are relatively low 
throughout the cell cycle, but increased in early G1-phase, when a functional 
nucleolar structure has not been reassembled, yet (Klein and Grummt, 1999; David-
Pfeuty, 1999). 
 
 
1.8 The Cdk-inhibitor Flavopiridol impairs ribosome biogenesis 
In 2005, the nucleolar proteome became available. 692 proteins were found to 
reproducibly localize in the nucleolus, confirming earlier studies in yeast (Andersen 
et al., 2005; Huh et al., 2003). Interestingly, 7 % of the nucleolar proteome are 
associated with cell cycle regulating proteins, including 15 kinases and phosphatases 
with potential regulatory function in ribosome biogenesis. Inhibition of kinase 
activity is a promising and successfully proven approach for the development of 
novel small molecule inhibitors. Non-genotoxic small molecule inhibitors like 
Flavopiridol (FL) are superior to a wide range of commonly used drugs, which often 
intercalate or alkylate DNA and cause frameshift mutations, lesions, or cross-links. 
Figure 7. The nucleolus as stress sensor. (A) Nucleolar integrity is maintained under normal conditions. 
Ribosome biogenesis is functional and active Hdm2, which ubiquitinates p53 for proteasomal degradation, 
keeps p53 levels low. (B) The nucleolus disrupts under stress. Nucleolar disintegration induces 
nucleoplasmatic translocation of nucleolar ribosomal proteins (rP), which bind Hdm2 and inhibit its activity. 
p53 no longer can be actively degraded, accumulates in the nucleus, and triggers cell cycle arrest and 
apoptosis by inducing critical downstream targets (e.g. p21 or Bax) (adapted from Drygin et al., 2010). 
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FL is a semi-synthetic flavonoid, derived from Amoora rohituka and Dysoxylum 
binectariferum. In 1992, Kaur and colleagues found that FL inhibits cell cycle 
progression. Cell cycle inhibition was initially explained by inactivation of Cdk1 and 
Cdk2 (Carlson et al., 1996). In vitro studies with recombinant Cdks revealed that FL is 
a pan-specific Cdk-inhibitor, which inhibits different Cdks at different concentrations 
(Newcomb, 2004). FL inactivates Cdk1, Cdk2, and Cdk4 with a dissociation constant 
(Ki) of around 50 nM (Carlson et al., 1996). Cdk7 and Cdk8 are less potently inhibited 
(Losiewicz et al., 1994). Later on, it became evident that Cdk9 is the primary target of 
FL. Cdk9 is inactivated by FL in vitro with an Ki of 3 nM, a five to ten fold lower 
concentration than required for an effect on any other Cdk (Chao et al., 2000; Chao 
and Price, 2001; Schmerwitz et al., 2011).  
Many small molecules induce cell cycle arrest or apoptosis by p53 induction. 
Do they inhibit ribosome biogenesis as well? Indeed, 47S rRNA processing is highly 
sensitive to the Cdk-inhibitors. It has been shown that Cdk-inhibitors like 5,6-
Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) or Roscovitine strongly inhibit 
processing of the 47S rRNA primary transcript, whereas transcription rates 
apparently remain unaffected (David-Pfeuty et al., 2001; Sirri et al., 2002; Schlosser et 
al., 2003; Louvet et al., 2005). In my previous work, I have extended these findings by 
testing a comprehensive panel of 36 drugs on their inhibitory potential on ribosome 
biogenesis. I found that > 50 % of drugs interefere with rRNA synthesis. 
Interestingly, low nanomolar concentrations of FL severely block 47S rRNA 
processing, cause nucleolar disruption, and induce p53 (Burger et al., 2010). FL is 
currently tested in clinical trials for therapy of relapsed chronic lymphocytic 
leukaemia (CLL). Patients with a genetically high-risk CLL are highly responsive to 
FL (Byrd et al., 2007; Phelps et al., 2009; Lin et al., 2009). In addition, FL causes 
haematological improvement in Pentostatin and Rituximab refractory hairy 
leukaemia (Jones et al., 2011). 
 
 
1.9 Scope of this thesis (Aufgabenstellung) 
Ribosome biogenesis is essential for growth and proliferation. It consumes an 
enormous amount of cellular energy and requires hundreds of different RNAs and 
proteins transcribed by all three RNA polymerases. Its functionality is a prerequisite 
for low levels of p53. Although the intimate connection between a functional 
nucleolus and its requirement to actively destabilize p53 is widely accepted, little 
effort has been carried out so far to investigate the molecular details of mammalian 
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ribosome biogenesis regulation and its therapeutic relevance. Ribosome biogenesis is 
often deregulated in cancer and its inhibition triggers a p53 stress response, cell cycle 
arrest in G1-phase, and apoptosis. Novel drugs that target ribosome biogenesis may 
be a promising approach for selective inhibition of growth and proliferation in cancer 
cells. In this context, non-genotoxic inhibition of 47S rRNA processing by FL 
treatment is of particular interest. How is 47S rRNA processing regulated? Which 
kinase(s) regulate(s) 47S rRNA processing? Which factors are rate limiting for 47S 
rRNA processing? This thesis aims to (i) shed light on mechanistic details of 47S 
rRNA processing upon FL treatment, (ii) identify the kinase(s) involved in the 
regulation of 47S rRNA processing, (iii) investigate the nucleolus as a sensor of stress, 
and (iv) present an approach for non-genotoxic inhibition of ribosome biogenesis.  
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2. RESULTS 
 
 
 
 
 
2.1 47S rRNA processing requires Cdk9 
In previous work, I tested a comprehensive panel of classical 
chemotherapeutic drugs and small molecule inhibitors for their impact on rRNA 
synthesis. Building on that, FL-mediated inhibition of 47S rRNA processing was 
unravelled in human U2OS cells and mouse embryonic fibroblast (MEF) cells. A 
panel of additional Cdk-inhibitors was tested on their ability to interfere with 47S 
rRNA processing (Fig. 8). rRNA synthesis was studied by metabolic labelling of 
rRNA with [32P]-ortho-phosphate. While 47S rRNA processing was functional after 
treatment with Compound 3 (Cdk2-inhibitor), or TG003 (Cdc2-like-kinase-inhibitor), 
treatment with Actinomycin D (ActD) or CGP74514A (Cdk1-inhibitor) strongly 
impaired the production of the 47S rRNA primary transcript (phenotype 1). 
Strikingly, five different Cdk9-inhibitors blocked 47S rRNA processing, but allowed 
its production (phenotype 2). Thus, chemical inhibition of Cdk9 causes a 47S rRNA 
processing defect. 
Small molecule Cdk-inhibitors allow inhibitions of Cdks, but have drawbacks 
with specificity and toxicity. To investigate the requirement of individual kinases for 
47S rRNA processing, I applied an RNAi approach for the selective knockdown of a 
panel of 30 candidate kinases (Table 2). A candidate list was assembled by three 
criteria: (i) it includes major Cdks; (ii) it includes all known kinases of the nucleolar 
proteome (Leung et al., 2006); and (iii) it includes kinases with a substrate 
phosphorylation motif identical to the Cdk9 substrate (SP-motif). U2OS cells were 
transiently transfected with short interfering (si)RNA targeting mRNAs of candidate 
kinases or with control siRNAs for mRNAs of luciferase, nucleolar CALM/AF10-
interacting protein CATS (Archangelo et al., 2008) and the rRNA processing factor 
Pescadillo 1 (Pes1) (Hölzel et al., 2005). Knockdowns of the majority of kinases 
impaired neither rRNA transcription nor processing. In contrast, the knockdown of 
Cdk5, Cdk6, and Cdk9 displayed a strong rRNA synthesis phenotype 
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(Fig. 9A, only a selected number of knockdown experiments is displayed). 
Knockdown of Cdk5 diminished the levels of the 47S primary transcript, suggesting 
that Cdk5 is crucial for rRNA transcription. Consequently, the levels of 32S, 28S, and 
18S rRNA were also reduced upon Cdk5 knockdown. In contrast, Cdk6 and Cdk9 
knockdown specifically blocked rRNA processing. Cdk9 knockdown mimicked the 
impact of Cdk-inhibitors on rRNA synthesis best. While the production of the 47S 
Table 2. Candidate kinases for RNAi screen. 30 kinases were chosen. (n): nucleolar kinase; Pescadillo1 
(Pes1) is a ribosomal processing factor (positive control), CALM/AF-10 interactor CATS is a nucleolar 
proliferation marker (negative control). 
 
Figure 8. Cdk9-inhibitors block 47S rRNA processing. (A) Scheme of metabolic [32P]-ortho-phosphate 
labelling. (B) Impact of Cdk-inhibitors on 47S rRNA processing. U2OS cells were treated with drugs for six 
hours and labelled. rRNA signals were analyzed by autoradiography. Compound 3 was used as Cdk2-
inhibitor, TG003 as Cdk13-inhibitor, Actinomycin D as transcription inhibitor, CGP74514A as Cdk1-inhibitor, 
Flavopiridol, DRB, Roscovitine, Cdk9-inhibitor II, and KM05283SC as Cdk9-inhibitors. 28S EtBr: loading 
control in this and subsequent experiments. ctrl.: 0.1 % DMSO. 
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primary transcript appeared to be unchanged, a strong reduction was observed for 
intermediate 32S rRNA and mature 28S and 18S rRNAs. In fact, 28S rRNA 
maturation was reduced by > 50 % as quantified by PhosphorImager analysis. Cdk6 
knockdown also blocked 47S rRNA processing. However, inhibition of 47S rRNA 
processing was not as pronounced as after Cdk9 knockdown. Strong defects in 47S 
rRNA processing could not be observed after knockdown of other Cdks. Knockdown 
efficacies were monitored by Western blot analysis (Fig. 9B). Most siRNAs were 
Figure 9. Cdk9 knockdown inhibits rRNA processing. (A) rRNA synthesis after Cdk9 knockdown. U2OS 
cells were seeded and cultured over night. Cells were transfected twice with siRNA (100 nM) for six hours at 
two consecutive days. Analysis of labelled rRNA was performed as described in Materials and Methods. 
Inhibition of rRNA processing was measured by autoradiography. Knockdown efficacy of Cdks in are 
displayed in %. Labelled rRNAs were quantified by a PhosphorImager and AIDA software. rRNA ratios were 
calculated and normalized to control cells (siLuc). Pes1 and CATS knockdown served as positive and 
negative controls, respectively. ctrl.: untreated cells. (B) Cdk knockdown controls. Knockdown efficacy was 
monitored by Western blot analysis using specific antibodies. Pes1 and #-Tubulin served as loading controls. 
(C) Knockdown efficacy was quantified by AIDA software. Cdk levels were calculated relative to control cells 
(siLuc) set as 1. n.d.; not determined. 
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highly efficient and depleted 75-95 % of the endogenous proteins (Fig. 9C). Thus, 
Cdk9 knockdown induces a 47S rRNA processing defect similar to the processing 
defect observed upon FL treatment, suggesting that Cdk9 is the prime candidate to 
regulate mammalian 47S rRNA processing.  
 
2.1.1 The nucleolar isoform of Cdk9 has no impact on rRNA processing 
Two forms of Cdk9 with a molecular weight of 42 kDa and 55 kDa have been 
described in mammalian cells. The Cdk955 isoform carries an N-terminal extension of 
117 amino acids and is generated from an mRNA that originates from a second 
promoter located upstream of the start point of transcription used to generate mRNA 
encoding Cdk942 (Shore et al., 2003; Shore et al., 2005). The relative abundance of 
Cdk955 and Cdk942 changes in various cell types upon differentiation. Interestingly, 
epitope-tagged Cdk942 localizes diffusely in the nucleoplasm, while Cdk955 
accumulates in the nucleolus (Liu and Herrmann, 2005). I asked therefore, if 
knockdown of the nucleolus specific Cdk955 alters processing of rRNA. Transfection 
of U2OS cells with a siRNA for the first exon of Cdk955 reduced steady state levels of 
nucleolar form of Cdk9 by > 70 %, while expression of Cdk942 remained unaffected 
(Fig. 9B). Surprisingly, an rRNA processing defect could not be detected after Cdk955 
knockdown (Fig. 9A), indicating that the large form of Cdk9 has apparently no 
specific function in rRNA processing and that nucleoplasmic Cdk942 is critical for 
processing of rRNA. 
 
2.1.2 Cdk9-mediated rRNA processing is conserved in yeast 
Having established that Cdk9 regulates 47S rRNA processing in human cells, I next 
asked, whether Cdk9 is also required for rRNA processing in the baker’s yeast S. 
cerevisiae (Fig. 10). Two complexes functionally reconstitute the mammalian Cdk9 
activity in yeast. On the one hand, the CTK kinase complex, which consists of Ctk1 
kinase, Ctk2 cyclin, and a Ctk3 subunit, on the other hand the Cdk/cyclin complex 
Bur1/2 (Wood and Shilatifard, 2006). Conditional knockout strains were created to 
measure rRNA synthesis after depletion of Ctk1 or Bur1/2. In brief, the endogenous 
CTK1 and BUR2 genes were deleted and replaced by stably transformed, 
recombinant, TAP-tagged versions under control of a Galactose-inducible promoter 
(GAL::CTK1-TAP; GAL::BUR2-TAP). Note that Bur2 is the stabilizing cyclin of the 
Bur1 kinase. Bur2 cyclin depletion destabilizes the Bur1 kinase quantitatively (Wood 
et al., 2005). Ctk1-TAP and Bur2-TAP were expressed at comparable amounts in 
presence of Galactose-containing YPG medium. Medium switch to Glucose- 
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containing YPD medium represses the expression of Ctk1-TAP and Bur2-TAP. Note 
that yeast cell growth is slightly reduced after Ctk1 depletion, but remains 
unchanged after Bur1/2 depletion (Röther and Strässer, 2007). Depletion of Ctk1-
TAP and Bur2-TAP was monitored by Western blot analysis (Fig. 10A) and rRNA 
synthesis was measured by 32P metabolic labelling (Fig. 10B). Ctk1 depletion reduced 
rRNA synthesis globally. Production of 35S rRNA, as well as maturation of 25S and 
18S rRNA was reduced. In contrast, Bur1/2 depletion selectively blocked 27S rRNA 
processing compared to wild type cells, but had no inhibitory effect on production 
and processing of the 35S rRNA primary transcript. Instead, a slight accumulation of 
the 35S primary transcript could be detected upon Bur1/2 depletion. Thus, Bur1/2 
depletion causes an rRNA processing phenotype, which, although not identical, is 
similar to Cdk9 knockdown. I conclude that Ctk1 and Bur1 have crucial functions in 
rRNA synthesis, although both knockout phenotypes differ from Cdk9 knockdown 
in mammalian cells. 
 
 
2.2 Defective 47S rRNA processing feeds back on RNAP I transcription 
To understand the dynamics of rRNA synthesis upon Cdk9 inactivation, I 
measured mammalian 47S rRNA processing in time kinetic experiments (Fig. 11). 
Confirming previous results, treatment of cells with FL inhibited 47S rRNA 
processing. However, when applying 32P labelling experiments with various chase 
times, I noticed that FL not only blocked 47S rRNA processing, but also altered the 
kinetics of 47S rRNA accumulation (Fig. 11A). Control cells showed a rapid 
Figure 10. Impact of yeast Ctk1 or Bur1/2 depletions on rRNA synthesis. (A) Depletion of Ctk1 and 
Bur1/2. Conditional knockout yeast strains were created as described in Materials and Methods. Knockout 
was monitored by Western blot analysis with a protein-A antibody, specifically recognizing TAP-tagged 
proteins. Phosphoglycerate kinase 1 (PGK1): loading control. Dr. Britta Coordes performed Western blot 
analysis. (B) Ctk1 is required for rRNA transcription and processing, Bur1/2 for rRNA processing. Yeast 32P 
metabolic labelling was performed as described in Material and Methods. ctrl.: wild type yeast W303. 
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incorporation of 32P label in 47S rRNA already after 30 minutes of chase, with a 
maximal incorporation of label after two hours, and a decline after three hours. In 
contrast, incorporation of label in FL-treated cells was low after 30 minutes, but 
steadily increased, and reached a value similar to control cells after three hours. A 
diminished incorporation of 32P label in 47S rRNA would be consistent with a 
reduced transcription rate of RNAP I in FL-treated cells.  
To confirm this assumption, a second rRNA labelling experiment was 
conducted, using 4-thiouridine (4sU), a thiol-group containing, photo-reactive 
nucleoside with high cell permeability that can be introduced into eukaryotic cells 
and allow non-disruptive metabolic labelling of nascent RNA within minutes 
(Melvin et al., 1978). A 4sU-tagged RNA fraction can be analyzed by thiol-specific, 
covalent biotinylation, and subsequent purification on streptavidin-coated beads 
(Cleary et al., 2005). The 4sU-tagged, nascent RNA fraction was separated in a 
Figure 11. Inhibition of 47S rRNA processing feeds back on RNAP I transcription. (A) Flavopiridol 
diminishes 47S rRNA transcription. U2OS cells were treated with FL or ActD for six hours and labelled with 
[32P]-ortho-phosphate as indicated. Relative 32P signals for 47S rRNA were plotted. The 47S rRNA signal 
intensity for control cells (0.1 % DMSO) after two hours (lane 4) was set as 1. (B) Analysis of 47S rRNA 
transcription after Flavopiridol measured by 4sU-tagging. Cells were treated with FL and 4sU as indicated. 
4sU-tagged RNA was purified from total RNA by biotin-streptavidin, separated by gel-electrophoresis, and 
stained with EtBr (see Materials and Methods for details). Relative EtBr signals for 47S rRNA were plotted and 
the 47S signal in control cells (0.1 % DMSO) after 180 minutes (lane 7) was set as 1. 
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denaturing agarose gel and stained with ethidium bromide (Fig. 11B). A faint band 
corresponding to the 47S rRNA became visible in control and FL-treated cells already 
45 minutes after labelling, increased in intensity after 60 minutes, and reached steady 
state levels after 120 to 180 minutes in control and FL-treated cells. Notably, FL 
causes a slight, but significant reduction in nascent 47S rRNA production. A 32S 
rRNA processing intermediate became visible in control cells after 60 minutes, 
followed by the appearance of mature 18S and 28S rRNAs after two and three hours. 
In control cells, > 90 % of 4sU-labelled rRNA was processed to 32S, 28S, and 18S 
rRNA after three hours. In contrast, processing of the 47S rRNA precursor into 
immature 32S rRNA, or mature 28S rRNA and 18S rRNA did not occur in presence 
of FL. I conclude that the synthesis and turnover rates of 47S rRNA in FL-treated 
cells could be significantly reduced compared to control cells.  
 
 
2.3 Cdk9 is required for correct 3’ETS processing 
While 47S rRNA is produced normally in FL-treated cells (albeit at reduced 
rates), its processing into intermediate and mature rRNA forms is blocked entirely. 
However, the basis for this blockage is unclear. Therefore, I analyzed whether 47S 
rRNA displays structural abnormalities in FL-treated cells, which might be causative 
for the processing defect. 3’ end formation downstream of the 3’ ETS is the first 
processing step for the primary ribosomal transcript (Richard and Manley, 2009). 
Removal of 3’ETS as well as the 5’ leader sequence of the 5’ETS have been described 
as subsequent processing steps, which lead to the formation of the 45S rRNA 
processing intermediate (Mullineux and Lafontaine, 2012). Unfortunately, 47S and 
45S are large molecules with similar sizes and cannot be separated in agarose gel 
electrophoresis. Therefore, the signal marked as 47S rRNA in Northern blot 
hybridizations represents always a mixture of both 45S and 47S rRNAs, if 
hybridizations are performed with 45S-specific probes. The sequence composition of 
the rRNA primary transcript was analyzed with the help of 14 hybridization probes, 
which are distributed along the 47S rRNA sequence (probes 1 to 9) and downstream 
thereof (probes 10 to 14) (Fig. 12, upper panel). U2OS cells were treated with FL for 
six hours, total RNA was isolated, and analyzed by Northern blot hybridization. I 
could detect rRNA signals of a size of 47S with hybridization probes 1 to 9 in the 
control situation. The signal normally is indicative for 47S rRNA properly 
processed/terminated at the termination site (T). As expected, signals for probes 10 
to 14 downstream of the T-site were not detected in control cells. The signals 
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obtained for 47S rRNA from FL-treated cells differed from control cells in several 
aspects. Each of the 47S signals for probes 1 to 6 was reduced by a factor of two in 
rRNA derived from FL-treated cells. Since FL-treated cell have a 47S rRNA 
processing defect, the observed reduction may be explained by a lack of properly 
produced 45S rRNA in the fraction of rRNA running at the size of 47S. In line with 
that, FL stabilized 47S rRNA (probes 7 to 9). I conclude that FL significantly changed 
the ratio of 45S/47S rRNA. The second remarkable difference for 47S rRNA in FL-
treated cells is the appearance of hybridization signals for probes 10 to 14, indicating 
that FL causes a specific defect of 47S rRNA processing in the 3’ETS region, which 
leads to the stabilization of 3’-extended 47S rRNA. After 24 hours FL treatment, 47S-
extended rRNA further accumulated by a factor of three to eight (probes 1 to 13). 
Elevated levels of 47S-extended rRNAs could also be detected after Cdk9 
knockdown. Taken together, the data show that 47S rRNA can no longer be 
processed properly upon Cdk9 inactivation, due to a processing defect in the 3’ETS 
region at or downstream of the T-site. The processing defect stabilizes an extended 
47S rRNA, which accumulates over time. 
 
 
Figure 12. Cdk9 inactivation causes defective 3’ETS processing. U2OS cells were treated with FL or 
siRNA against Cdk9. Total RNA was isolated and analyzed by Northern blot hybridization with probes for 
5’ETS, ITS-1, ITS-2, 3’ETS, or sequences downstream of 3’ETS (probes 1-14). Signals were analyzed by 
autoradiography and quantified by a PhosphorImager. 47S rRNA signals were plotted relative to signals from 
0.1 % DMSO-treated or siLuc-transfected cells (ctrl.) set as 1. T: termination site, T-stretch: tymidine stretch. 
Grey box: rRNA forms with a size of 47S (47S-extended, 47S, and 45S rRNA). 
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2.4 Processing of 47S rRNA is dependent on RNAP II transcription 
Having established that Cdk9 is required for 47S rRNA processing, I next 
investigated the molecular details of this requirement. Cdk9 is the active component 
of pTEFb, which phosphorylates the RNAP II CTD to enable transcription elongation 
(Peterlin and Price, 2006). I assumed that Cdk9 inactivation might prevent RNAP II 
transcription and thereby interferes with 47S rRNA processing. To test this 
hypothesis, contribution of RNAP II transcription to 47S rRNA processing was 
analyzed directly by using #-amanitin (#-Am), a highly specific inhibitor of RNAP II 
transcription (Kedinger et al., 1971). #-Am binds the largest subunit of RNAP II 
(Rpb1) with high affinity and traps RNAP II in an inactive conformation that 
prevents nucleotide incorporation, translocation, and triggers RNAP II degradation 
in vivo (Bushnell et al., 2002; Kaplan et al., 2008; Brueckner and Cramer, 2008; 
Nguyen et al., 1996). I used ActD, FL, and #-Am to inhibit RNAP II transcription in 
U2OS cells and measured 47S rRNA processing in 32P labelling experiments (Fig. 
13A). ActD blocked RNAP I activity entirely and no signals for 47S rRNA or 
downstream forms could be detected. Remarkably, both FL and #-Am did not 
prevent production of the 47S rRNA precursor, but impaired its processing. 32S, 28S, 
and 18S rRNA levels were strongly reduced. 47S rRNA processing was also 
measured in HeLa cells, which express an #-Am-resistant version of RNAP II. 
Strikingly, 47S rRNA processing is completely functional in these cells in presence of 
#-Am (Fig. 13B). Importantly, #-Am induced the same 3’ETS processing defect in 
U2OS cells, as seen after Cdk9 inactivation (Fig. 13C), and stabilized a 3’-extended 
47S rRNA. This indicates that RNAP II transcription is required for correct 
processing of the 47S rRNA primary transcript at the 3’ end. The data strongly 
suggest that the Cdk9-dependent rRNA processing phenotype is caused by 
abrogation of RNAP II transcription.  
RNAP II synthesizes different RNA species, which can be divided in two 
categories: protein-coding messenger (m)RNA and non-coding RNAs such as micro 
(mi)RNA, short-interfering (si)RNA, small nuclear (sn)RNA, or small nucleolar 
(sno)RNA involved in posttranscriptional gene regulation and RNA metabolism (Fig. 
14A). Although RNAP II regulates expression of many genes encoding ribosomal 
proteins and processing factors, it is unclear to what extend the different RNAP II-
dependent RNAs contribute to 47S rRNA processing. A number of experiments were 
designed to dissect the specific requirement of mRNA synthesis, small RNA 
biogenesis, and snoRNA synthesis for 47S rRNA processing.  
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2.4.1 Inhibition of translation does not induce defective 3’ETS processing 
mRNAs are the most prominent RNAP II-dependent transcripts. Cdk9 is 
required for coordinated transcription, processing, and surveillance of mRNAs  
(Chao and Price, 2001). mRNAs by themselves are not functional. They need to be 
translated. If an affected mRNA for a highly labile protein was required for 3’ETS 
processing of 47S rRNA, inhibition of translation should deplete such a factor rapidly 
Figure 13. Processing of 47S rRNA is dependent on RNAP II transcription. (A) Inhibition of 47S rRNA 
processing in U2OS cells after treatment with #-amanitin (#-Am). Cells were treated with ActD, FL, or #-Am 
for six hours, followed by labelling with 32P. rRNA ratios were calculated and normalized to rRNA ratios 
derived from control cells (0.1 % DMSO). (B) Normal processing of 47S rRNA in #-amanitin-resistant cells. 
HeLa cells were treated with #-Am for various time points. 47S rRNA processing was measured as described 
and normalized to rRNA ratios derived from control cells (0.1 % DMSO). (C) Inhibition of RNAP II transcription 
stabilizes a 3’-extended form of 47S rRNA. Cells were treated with #-Am (10 !g/ml). Total RNA was isolated 
an analyzed by Northern blot hybridization with indicated probes. T: termination site, T-stretch: tymidine 
stretch. 
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and trigger an rRNA processing defect. To test this hypothesis, U2OS cells were 
treated with two translational inhibitors, Cycloheximide (CHX) and 
Homoharringtonine (HHT), and rRNA processing was analyzed in 32P labelling 
experiments (Fig. 14B). Effective inhibition of translation was monitored for the 
short-lived c-Myc protein (Fig. 14C). Both CHX and HHT displayed a strong rRNA 
processing defect, yet the phenotype of this defect differs markedly from the 
phenotype observed in cells treated with FL. While both drugs reduced 28S rRNA 
maturation (28S/47S ratio), the 32S/47S ratio was reduced solely in FL-treated cells, 
Figure 14. Inhibition of translation does not induce a 3’ETS 47S rRNA processing defect. (A) Scheme of 
major RNAP II-dependent transcripts: messenger RNAs (mRNAs), micro RNAs (miRNAs), short interfering 
RNAs (siRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs). (B) Impact of 
translation inhibitors on rRNA processing. U2OS cells were treated with FL or translation inhibitors 
Cycloheximide (CHX), or Homoharringtonine (HHT) for six hours. Metabolic labelling was performed and 
rRNA signals were measured by autoradiography. Normalized ratios were calculated relative to control cells 
(0.1 % DMSO). (C) Efficient depletion of short-lived c-Myc protein after treatment with translation inhibitors. 
U2OS cells were treated with FL, CHX, or HHT for six hours. Whole cell lysates were prepared, separated by 
SDS-PAGE and analyzed by Western blot with specific antibodies. Protein levels were quantified by AIDA 
software and compared to control levels (0.1 % DMSO) set as 1. (D) rRNA 3’ processing occurs in the 
presence of translational inhibitors. Cells were treated with CHX or HHT for six hours. RNA was isolated and 
analyzed by Northern blot hybridization with probes for 5’ETS, ITS-1, ITS-2, or 3’ETS sequences. T: 
termination site, T-stretch: tymidine stretch. ctrl.: 0.1 % DMSO. 
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but remained unchanged in cells treated with CHX or HHT. Importantly, 
translational inhibitors could also not induce a 3’-extended form of 47S rRNA, as 
observed in FL-treated cells (Fig. 14D). I conclude that translational inhibitors display 
an inhibitory effect on rRNA processing, but the phenotype is different from that 
observed in cells after Cdk9 knockdown or treatment with FL or #-Am. 47S rRNA 
processing is highly robust for inhibition of translation, indicating that defective 
mRNA synthesis is not the primary cause of defective 47S rRNA processing. 
 
2.4.2 Dicer1 knockout does not inhibit 47S rRNA processing  
Small non-coding RNAs such as miRNAs, siRNAs, or snRNAs are transcribed 
by RNAP II and processed by key processing enzymes Drosha, Dicer, and Argonaute 
in the RISC pathway. Dicer is a crucial exonuclease that processes non-coding RNA 
precursors into small double stranded 21-25 nucleotide long RNA fragments in the 
cytoplasm. I next asked whether 47S rRNA processing requires the function of small 
RNAs and is impaired in Dicer knockout cells? Conditional mouse embryonic 
fibroblast (MEF) Dicer1 knockout cells were used to answer this question. Cre-
dependent depletion of Dicer1 was monitored by Western blot analysis and 47S 
rRNA processing was measured by 32P metabolic labelling experiments after 
depletion (Fig. 15A). Interestingly, Dicer1 knockout strongly impaired maturation of 
28S and 18S rRNA forms by a factor of two to three relative to Dicer1+/+ control cells 
(Fig. 15B). Impaired 28S and 18S rRNA maturation is in line with the observed 
proliferation defect in Dicer1-/- cells (data not shown). Importantly, however, 
transcription of the 47S rRNA precursor and its processing efficacy into the 32S 
rRNA intermediate was fully functional in Dicer1-/- cells. The 32S/47S ratio, which is 
strongly reduced in FL-treated cells, remained unchanged in knockout cells. 
Consequently, no accumulation of the 47S rRNA could be observed with 3’ETS 
probes (Fig. 15C), as seen upon Cdk9 knockdown or FL treatment (Fig. 12). In 
summary, Dicer1 knockout strongly inhibits later rRNA processing steps and the 
formation of 18S and 28S rRNA, but does not affect the generation of 47S rRNA, or 
its proper 3’ processing, and processing to 32S rRNA. Thus, small RNAs produced in 
a Dicer1-dependent manner are probably not crucial for 3’ processing of 47S rRNA. 
 
2.4.3 Downregulation of snoRNAs after Cdk9 inactivation 
 The synthesis of almost all small nucleolar RNAs (snoRNAs) is dependent 
on RNAP II transcription. The human genome encodes approximately 400 annotated 
snoRNAs (www-snorna.biotoul.fr/). Most snoRNAs are transcribed as intronic 
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sequences within pre-mRNAs, while some are transcribed form their own promoters. 
SnoRNAs regulate various modification and processing steps of rRNA and a subset 
of them are essential in yeast and mammals. Processing of snoRNAs occurs in the 
nucleus and therefore happens largely independently of Dicer activity. I asked 
whether Cdk9 inactivation could alter the steady state levels of snoRNAs and thus 
has an impact on rRNA processing. A subset of 12 representative snoRNAs was 
selected, including those, which are essential for growth in yeast or have been 
described as essential for processing of rRNA before (Table 3).  
 I first tested how steady state levels of these snoRNAs are affected, when 
cells were treated with ActD or FL (Fig. 16A). Strong differences were seen for the 
stability of snoRNAs. While some snoRNAs (SNORD24, SNORD14B, SNORA8, and 
SNORD76) showed high stability in the presence of ActD and FL, levels of other 
Figure 15. Dicer1 knockout does not inhibit 47S rRNA processing. Mouse embryonic fibroblasts (MEFs) 
with floxed Dicer1 alleles were incubated with Cre-recombinase to create a Dicer1 knockout cell line. Two wild 
type (1C5, 1C1) and two knockout (1A11, 2G4) cell clones were single cell cloned and whole cell extracts 
were prepared. (A) Dicer1 knockout was monitored by Western blot analysis with Dicer1-specific antibodies. 
Dicer1 knockout blocks the maturation of 28S and 18S rRNA, but not the production of the 47S rRNA 
precursor or 32S rRNA intermediate. rRNA labelling was performed as described in Materials and Methods. 
(B) 32S rRNA levels are normal in Dicer1 knockout cells. (C) Dicer1 depletion does not affect correct 3’ETS 
processing. MEF cell lines 1C1 (Dicer1+/+) or 1A11 (Dicer1-/-) were used, RNA was isolated an analyzed by 
Northern blot hybridization with probes for 5.8S (A), 28S (B), or 3’ETS (C, D). T: termination site, T-stretch: 
tymidine stretch. 
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snoRNAs (SNOD117, SNOR73A, SNORA21, SNORA38A, SNORD3, SNORD22, 
SNORD14A, and SNORD118) diminished to a greater or lesser extend. ActD and FL 
treatment for six hours had no impact on steady state mRNA levels of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In contrast, levels of short-
lived c-myc mRNA were strongly reduced. I conclude that steady state levels of 
specific groups of snoRNAs are differently sensitive to inhibition of RNAP II 
transcription. I next asked, whether a decrease in snoRNA levels is also seen after 
Cdk9 knockdown. U2OS cells were treated with Cdk9-specific siRNA on two 
consecutive days and snoRNA levels were analyzed after additional 24 hours. Cdk9 
Figure 16. Downregulation of snoRNAs after Cdk9 inactivation or Nop56 knockdown. (A) SnoRNA levels 
in U2OS cells after treatment with ActD or FL for six hours. Northern blot analysis of RNA was performed with 
probes recognizing snoRNAs, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), or c-myc RNA. ctrl.: 0.1 
% DMSO. (B) SnoRNA levels after Cdk9 knockdown. Cells were transfected with Cdk9-specific siRNA, RNA 
was isolated 42 hours post transfection and analyzed as in (A). (C) Control of Nop56 mRNA depletion after 
knockdown. Quantitative real time PCR (qPCR) with specific primers was used to monitor knockdown efficacy 
(for details see Material and Methods). (D) Nop56 knockdown reduces SNORD3 (U3) and SNORD118 (U8) 
snoRNA levels. (E) Nop56 knockdown blocks 47S rRNA processing. Knockdown, Northern blot analysis, and 
quantitation were performed as described above. ctrl. knockdown: siLuc. 
 
Table 3. SnoRNA list. SnoRNAs are listed together with their host genes, target RNAs, and RNA 
modifications they are guiding. Six snoRNAs are required for rRNA cleavage. Eight snoRNA homologs have 
an rRNA synthesis phenotype in yeast. Me: Methylation; ": Pseudouridylation.  
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knockdown strongly reduced the same set of snoRNAs as treatment of cells with 
ActD or FL (Fig. 16B).  
 SnoRNAs are bound and stabilized by nucleolar proteins to form 
snoRNPs. In particular, box C/D snoRNAs like U3 and U8 require Nop56 for 
stabilization (Watkins and Bohnsack, 2011). Consequently, it was tested, whether 
Nop56 knockdown destabilizes U3 and U8 and inhibits 47S rRNA processing. Nop56  
knockdown was monitored by qPCR analysis, since no antibody was available (Fig. 
16C). Nop56 knockdown reduced U3 and U8 snoRNA levels (Fig. 16D) and blocked 
28S rRNA maturation by about 50 % (Fig. 16E). In summary, the results suggest that 
snoRNAs are critical Cdk9-dependent transcripts and highly relevant for 47S rRNA 
processing. Defective 3’ETS processing of 47S rRNA after Cdk9 inactivation is most 
likely caused by a specific defect in snoRNA biogenesis. 
 
 
2.5 Cdk9 inactivation triggers a nucleolar stress phenotype 
Various kinds of stress can trigger nucleolar disintegration, which is 
accompanied by p53 stabilization and induction of cell cycle arrest and/or apoptosis. 
Having established that Cdk9 inactivation blocks 47S rRNA processing, the 
induction of nucleolar stress after Cdk9 knockdown was assessed (Fig. 17). A couple 
of nucleolar proteins can serve as marker for the structural integrity of the nucleolus. 
Nucleophosmin (NPM1), for example, is a ubiquitously expressed phosphoprotein, 
which belongs to the nucleoplasmin family of chaperones. NPM1 has multiple 
functions in ribosome biogenesis, centrosome duplication, DNA repair, and stress 
response. Under normal conditions, NPM1 localizes predominantly in interphase 
nucleoli. After stress, the nucleolus disrupts and NPM1 translocates into the 
nucleoplasm (Colombo et al., 2011; Chan et al., 1996). Approximately 50 % of the cells 
comprised a disintegrated nucleolar structure after Cdk9 knockdown, charaterized 
by nucleoplasmatic NPM1 staining (Fig. 17A). p53 induction is a direct consequence 
of nucleolar disintegration and was analyzed in U2OS cells after Cdk9 knockdown 
(Fig. 17B). p53 was stabilized by a factor of three after Cdk9 knockdown, comparable 
to the induction seen after knockdown of the rRNA processing factor Pes 1 (Grimm 
et al., 2006). Nucleolar stress not only stabilizes, but also activates p53 (Hölzel et al., 
2010b). p53 activation is commonly associated with a cell cycle arrest and/or 
induction of apoptosis. Therefore, proliferation of U2OS cells was measured after 
Cdk9 knockdown (Fig. 17C). While Luciferase siRNA transfected cells continuously 
increased the cell index, transfection with siRNA specific for Cdk9 or Pes1 mRNA 
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reduced the cell index three-fold after 100 hours measurement. Thus, Cdk9 
inactivation impairs cell proliferation. In summary, Cdk9 inactivation disturbs 
nucleolar structure and function. It blocks 47S rRNA processing, thereby causing 
NPM1 translocation, p53 induction, and proliferation inhibition.  
 
 
2.6 Application of 4-thiouridine in rRNA labelling  
Metabolic in vivo labelling is a powerful approach to measure transcription 
and processing of nascent rRNA. Classical radioactive tracers like phosphate (32P) are 
Figure 17. Cdk9 knockdown causes nucleolar stress. NPM1 translocation, p53 stabilization, and reduced 
proliferation after Cdk9 knockdown. U2OS cells were transfected with siRNA (100 nM) on two consecutive 
days targeting the mRNA of Pes1 or Cdk9. (A) Cells were fixed with 2 % para-formaldehyde and 
permeabilized with PBS containing 0.04 % Triton X-100 42 hours post transfection. Endogenous NPM1 was 
stained with a specific primary antibody and detected with a Cy3-conjugated secondary antibody. Cell nuclei 
were stained with DAPI (100 ng/ml). The rate of NPM1 translocation after siRNA transfection is shown 
together with the number of cells analyzed. The nucleolus was classified as disintegrated, if NPM1 was not 
predominantly localized to the nucleolus. Scale bar: 5 !m. (B) Whole cell extracts were prepared and 
separated by SDS-PAGE. p53 levels were detected by Western blot analysis with a specific antibody. Pes1 
and #-Tubulin served as loading controls. p53 induction was plotted as x-fold induction relative to control p53 
levels (siLuc) set as 1. (C) Cells were cultured over night. Culture medium was replaced by transfection 
medium containing oligofectamine and siRNA (100 nM). Medium was replaced again with culture medium 
after six hours (1. transfection). Cells were cultured over night and siRNA transfection was repeated (2. 
transfection). Normalized cell number was measured in real time and compared to control cells (siLuc). The 
cell number correlates to changes in impedance, which is termed ‘cell index’ (see details in Material and 
Methods).  ctrl. knockdown: siLuc. 
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directly incorporated by RNAP I and allow convenient autoradiographic detection of 
major rRNA forms, as shown extensively in previous experiments. As an alternative, 
non-radioactive approach to measure rRNA synthesis, I applied the pyrimidine 
analog 4-thiouridine (4sU) for labelling and detetion of nascent rRNA (4sU-tagging) 
(Fig. 11B). 4sU-tagging with 10 µM 4sU for up to three hours rendered rRNA 
synthesis normal. However, standard 4sU-tagging protocols to analyze nascent 
mRNA synthesis typically use a 10- to 50-fold higher 4sU concentration for one hour 
(Cleary et al., 2005; Rabani et al., 2011; Schwanhäusser et al., 2011). Interestingly, a 
number of purine and pyrimidine analogs, such as 5-Fluorouracil (5-FU), 6-
Thioguanine (6-TG), or 6-Mercaptopurine (6-MP) have been shown to interfere with 
various cellular processes and induce cytotoxicity (Berger et al., 2002). 5-FU 
treatment, for example, strongly inhibits the RNA metabolism and ribosome 
biogenesis (Sun et al., 2007; Ghoshal and Jacob, 1994). Given that 4sU is a modified 
uridine analog that comprises high structural similarity to 5-FU, I next assessed 
whether 4sU could be a biological active compound that interferes with ribosome 
biogenesis at concentrations typically used in 4sU-tagging experiments.  
 
2.6.1 4sU inhibits rRNA synthesis 
U2OS cells were incubated with 100 µM 4sU, a concentration typically used to 
label nascent RNAs, and rRNA synthesis was assessed by 32P metabolic labelling 
experiments (Fig. 18). Remarkably, 4sU globally inhibited rRNA synthesis both at the 
Figure 18. 4sU inhibits rRNA synthesis. (A) 4sU inhibits both rRNA transcription and processing. U2OS 
cells were treated wit Uridine (Uri), 5-FU, or 4sU for six hours. Metabolic labelling was performed as described 
in Materials and Methods. Total 47S rRNA was visualized by EtBr staining under UV-light. ctrl.: 0.1 % DMSO. 
(B) Quantitation of rRNA synthesis after 4sU treatment. Total 47S rRNA levels were measured by quantitation 
of 47S EtBr UV-staining with ImageJ software, 32P-labelled 47S rRNA was quantified by a PhosphorImager 
and AIDA software. rRNA signals and normalized ratios were calculated and compared to control signals and 
ratios (0.1 % DMSO).  
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level of rRNA transcription and processing (Fig. 18A). Treatment with 4sU reduced 
both total, unlabelled and nascent, 32P-labelled 47S rRNA levels by about 75 % (Fig. 
18B). Processing of the remaining 25 % nascent, 32P-labelled 47S rRNA, which has 
been synthesized in presence of 4sU, was impaired by about 60 % compared to 
control cells (see normalized 28S/47S ratios). Treatment with 5-FU caused a 
profound inhibition of 28S rRNA maturation, but no significant inhibition of 47S 
rRNA production.  
Recent 4sU-tagging protocols try to avoid prolonged incubation times. 
Therefore, I analyzed the impact of short-term 4sU treatment on rRNA synthesis in 
time course experiments (Fig. 19A). 100 µM 4sU impaired rRNA synthesis after one 
to two hours of incubation (Fig. 19B). A concomitant decrease of 47S, 32S, 28S, and 
18S rRNA signals was detected with increasing 4sU incubation time (Fig. 19C).  
The dynamics of rRNA transcription and processing in presence of 4sU can be 
analyzed in chase kinetic experiments in more detail. U2OS cells were incubated 
with 5-FU or 4sU for six hours, labelled with 32P, and analyzed as indicated (Fig. 
20A). In control cells, 47S rRNA signals peaked after two hours of chase and 
decreased to 50 % after six hours of chase. 28S rRNA signals were not detectable 
Figure 19. Kinetics of 4sU-mediated rRNA synthesis inhibition. (A) Scheme of 32P labelling kinetics. rRNA 
synthesis was measured after different 4sU incubation times from zero to six hours. (B) 4sU impairs rRNA 
synthesis after one to two hours. U2OS rRNA was labelled in vivo with 32P, RNA was isolated, separated, and 
signals were detected by autoradiography. (C) Quantitation of 4sU time kinetics. 47S, 32S, 28S, and 18S 
rRNA signals were analyzed by a PhosphorImager and AIDA software. rRNA levels were plotted relative to 
untreated cells (lane 1) set as 1.  
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within the first hour and peaked after six hours of chase (Fig. 20B). In line with 
previous results, 5-FU treatment reduced 28S rRNA maturation, but slightly 
diminished 47S rRNA accumulation. While 28S rRNA was barely detectable after six 
hours of chase (lane 18), the 47S rRNA signal peaked after three hours of chase  (lane 
11). In contrast, 4sU strongly reduced 47S rRNA accumulation (Fig. 20C). 47S rRNA 
signals peaked after six hours of chase (lane 24) and comprised less than 50 % after 
two hours of chase (lane 22), the time point when 47S rRNA peaked in control cells. 
28S rRNA signals were barely detectable after one to three hours of chase in presence 
of 4sU (lanes 21-23), indicating that 4sU inhibits rRNA processing as well. Taken 
together, the data show that 4sU is a biologically active compound that globally 
inhibits rRNA synthesis when applied at high concentrations.  
 
 
Figure 20. 4sU diminishes rRNA transcription and processing. (A) Scheme of 32P in vivo metabolic 
labelling workflow. U2OS cells were incubated with Uridine (Uri), 5-FU, or 4sU for six hours. 32P was added for 
one hour (pulse) and cells were incubated for different chase times as indicated. (B) 4sU diminishes 47S 
rRNA production and 28S rRNA maturation. rRNA synthesis was analyzed as described in Materials and 
Methods. ctrl.: 0.1 % DMSO. (C) Quantitation of rRNA signals from (B). Signals were measured by a 
PhosphorImager and AIDA software and plotted as rRNA signals relative to 47S (lane 4) or 28S (lane 6) rRNA 
signals from control cells (0.1 % DMSO) set as 1. 
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2.6.2 4sU triggers nucleolar stress 
The potential of 4sU to induce key elements of nucleolar stress was assessed 
next (Fig. 21). Treatment with increasing concentrations of 4sU caused NPM1 
translocation with up to 40 % of the cells comprising disintegrated nucleoli (Fig. 21A) 
and stabilized p53 by a factor of 15 (Fig. 21B). I conlude that highly concentrated 4sU 
is sensed by the nucleolus and triggers a nucleolar stress response. 
 
 
 
 
 
 
 
 
 
Figure 21. 4sU causes nucleoplasmic translocation of nucleolar NPM1 and induces p53. (A) NPM1 
translocation. U2OS cells were treated with various concentrations of 4sU for six hours. Cells were fixed with 
2 % para-formaldehyde and permeabilized with PBS containing 0.04 % Triton X-100. Endogenous NPM1 was 
stained with a specific primary antibody and detected with a Cy3-conjugated secondary antibody. Cell nuclei 
were stained with DAPI (100 ng/ml). Scale bar: 5 !m. ctrl.: 0.1 % DMSO. (B) p53 stabilization. Cells were 
treated with 4sU as indicated. Whole cell extracts were prepared and separated by SDS-PAGE. p53 levels 
were detected by Western blot analysis. Pes1 serves as loading control. p53 induction was plotted as x-fold 
induction relative to p53 levels from control cells (0.1 % DMSO) set as 1. 
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3. DISCUSSION 
 
 
 
 
 
This thesis suggests an intimate link between Cdk9-mediated RNAP II 
transcription, snoRNA biogenesis, and rRNA processing. The discussion part 
contains a critical evaluation of the results and proposes a model for their 
explanation and integration into the current view. The clinical relevance of ribosome 
biogenesis will be discussed, too.  
 
 
3.1 Kinases at the interface between RNAP II transcription and rRNA 
processing 
Kinases are key regulatory players. Although a large body of knowledge exists 
for many kinase-mediated cellular processes, evidence for kinases involved in rRNA 
processing is limited. So far, four kinases have been shown to be required for 
mammalian rRNA processing. Depletion of human (h)Rio kinase family members 
hRio1, hRio2, or hRio3 specifically inhibits 18S rRNA maturation (Widmann et al., 
2012; Zemp et al., 2009; Baumas et al., 2012). The Nol9 kinase regulates processing of 
32S rRNA into mature 28S and 5.8S rRNA by an unknown mechanism (Heindl and 
Martinez, 2010). Inactivation of the hRio kinase family and Nol9 blocks later rRNA 
processing steps. In contrast, studies with Cdk-inhibitors from others and our 
laboratory suggest a role for Cdks in early processing of the rRNA precursor. This 
work is based particularly on the observation that Flavopiridol (FL), a pan-specific 
Cdk-inhibitor, blocks 47S rRNA processing. To define the target of FL with relevance 
in 47S rRNA processing, a combination of genetic depletions and chemical inhibitors 
was applied. Both approaches displayed Cdk9 as critical regulator of 47S rRNA 
processing. Notably, the rRNA processing phenotype after Cdk9 knockdown was 
similar, but not identical to FL treatment. Complete inactivation of Cdk9 by RNAi is 
difficult to achieve. A stable pool of inactive Cdk9 is associated with the small 
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nuclear RNA 7SK and the HEXIM1 protein. On demand, the cell can gain additional 
active Cdk9 by dissociating it from 7SK RNA and HEXIM1 (Nguyen et al., 2001; 
Yang et al., 2001; Michels et al., 2003). In contrast, FL is a direct modulator of Cdk9 
activity. It binds the ATP-binding pocket of Cdk9 quantetatively with its benzopyran 
part (De Azevedo et al., 1997; Baumli et al., 2008). This may explain why 47S rRNA 
processing is less potently inhibited after knockdown than after chemical inhibition 
of Cdk9.  
Previous reports described a specific nucleolar form of Cdk9, Cdk955, 
generated from an mRNA that originates from a promoter upstream of the regular 
Cdk942 promoter. Surprisingly, the specific knockdown of Cdk955 did not inhibit 
rRNA synthesis, suggesting that the reason for the 47S rRNA processing defect 
rather lies in the nucleoplasm and is caused by Cdk942. Cdk9 is the catalytic subunit 
of the positive transcription elongation factor b (pTEFb), which augments RNAP II 
transcription, but also phosphorylates negative regulators of RNAP II like Spt4/5 
and NELF. I therefore wondered, if RNAP II could be the cellular target that is 
responsible for defective 47S rRNA processing. Various kinases have been described 
to modulate RNAP II transcription by changing the phosphorylation patterns of the 
RNAP II CTD in concert with Cdk9. For example, the Brd4 kinase binds the CTD and 
regulates RNAP II transcription either directly by phosphorylation of the CTD or 
indirectly by Cdk9 recruitment (Devaiah et al., 2012; Wu and Chiang, 2007). The 
DNA-activated protein kinase (DNA-PK) can phosphorylate the CTD at serines and 
threonines with comparable efficacy (Lu et al., 1992; Dvir et al., 1993). Brd4- and 
DNA-PK-mediated CTD phosphorylations include the classical Cdk9 residue serine-
2. However, Brd4 and DNA-PK were not regarded as FL-sensitive candidate kinases, 
since they modify the CTD only in vitro and are both atypical kinases. In fact, Brd4 is 
insensitive to FL-treatment (Devaiah et al., 2012). Cdk7 and Cdk8 are bona fide CTD-
kinases, which introduce CTD phosphorylations critical for RNAP II initiation and 
co-transcriptional processing. Recent work defined Cdk12 and Cdk13 as CTD-
kinases, too. Depletion of Cdk12 alters the CTD phosphorylation status, suggesting a 
functional interplay with Cdk9 in the regulation of RNAP II transcription 
(Bartkowiak et al., 2010). Surprisingly, neither inactivation of Cdk7, Cdk8, Cdk12, 
nor Cdk13 significantly changed rRNA processing. Cdk7 and Cdk8 are classical 
CTD-kinases for serines-5 and -7 required for initiation, but do not phosphorylate 
serine-2 required for elongation. I conculde that RNAP II elongation, rather than 
initiation, is crucial for 47S rRNA processing. However, Cdk redundancy could mask 
possible rRNA processing phenotypes, as shown for Cdk2, Cdk3, and Cdk4, which 
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are dispensable for cell cycle progression (Tetsu and McCormick, 2003; Ortega et al., 
2003). One should also regard possible issues with knockdown efficacy and 
specificity. Although the requirement for Cdk9 in 47S rRNA processing was 
confirmed by knockdowns with two independent siRNAs, knockdown efficacy has 
been monitored only with a subset of kinases and in case an rRNA synthesis 
phenotype was visible. Importantly, the RNAP II-specific inhibitor #-amanitin 
phenocopied the Cdk9-dependent 47S rRNA processing phenotype by inducing the 
same phenotype as FL. This result unambiguously proves that maintenance of RNAP 
II transcription is required for 47S rRNA processing. I conclude that Cdk9 
inactivation affects the synthesis of RNAP II-dependent transcripts critical for 47S 
rRNA processing. Whether Cdks different from Cdk9 definitely have no function 
rRNA processing or may assist Cdk9 in rRNA processing, requires further 
investigations. 
 
 
3.2 Adaption of RNAP I transcription to 47S rRNA processing 
Inhibition of RNAP II activity by #-amanitin or Cdk9 inactivation induced a 
specific 47S rRNA processing defect in the 3’ETS region. The defect is characterized 
by the occurrence of additional sequences downstream of the termination site (T) in 
47S rRNA. In principle, this phenotype could be caused either by defective 
termination of RNAP I at the T-site or by an rRNA processing defect. In the first case, 
RNAP I would terminate immediately downstream of the T-site without transcribing 
sequences further downstream. Alternatively, RNAP I transcription is not affected, 
but the processing of rRNA at the T-site is impaired. Several pieces of evidence argue 
for the second scenario. Inhibition of RNAP II activity or Cdk9 inactivation 
prevented termination of RNAP I at the T-site. Sequences further downstream were 
transcribed, stabilized, and accumulated as unprocessed 47S-extened rRNA. 
Termination probably occurred at the first tymidine-stretch downstream. Not only 
sequences downstream of the T-site remained associated with the precursor, but also 
the 3’ETS itself, which usually is rapidly removed from 47S rRNA. There is also no 
indication for the removal of the leader sequence of the 5’ETS from the primary 
transcript, and no evidence for processing of ITS-1 and ITS-2 sequences. This 
suggests that all sites for endonucleolytic processing in the primary transcript are not 
targeted by the respective nuclease, if RNAP II is inhibited. 
Inhibition of RNA processing is commonly accompanied by the accumulation 
of an unprocessed precursor RNA. Indeed, 47S rRNA accumulation after FL- or #-
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Am treatment could be detected in Northern blot hybridizations, but not in 32P 
metabolic labelling experiments, even when displaying strong inhibition of 47S 
rRNA processing. The reason for this discrepancy was unclear. 32P metabolic 
labelling experiments are based on end-point analysis. However, end-point analysis 
is suboptimal to determine nascent 47S rRNA levels, since steady state could be 
reached within this period. Two labelling kinetics, with 32P and 4sU, assisted to solve 
this problem. Kinetic data revealed that FL or #-Am treatment reduced RNAP I 
transcription rate. The kinetic alterations of RNAP I transcription were masked in 32P 
metabolic labelling experiments, since defective 3’ETS processing is sensed by RNAP 
I transcription in a negative feedback loop. Thus, RNAP I transcription adapts to 
defective 3’ETS processing to harmonize rRNA synthesis. But how can a 3’ 
processing defect in 47S rRNA feed back on RNAP I transcription? It has been shown 
that the RNAP I termination region of active rDNA genes is physically and 
functionally linked to the promoter of the subsequent rDNA repeat by the SL1 
complex (Németh et al., 2008; Denissov et al., 2011). If RNAP I fails to terminate at 
the end of the gene due to a 3’ processing block, this failure may have direct impact 
on initiation of the next RNAP I molecule at the adjacent promoter. Consequently, 
the transcription rate is slowed down.  
Adaption of RNAP I transcription to reduced 47S rRNA processing raises the 
question, whether RNAP I and early rRNA processing are coupled events that 
mutually respond to each other. Interestingly, previous studies from our group 
showed that RNAP I occupancy is constantly high and remains unchanged upon 
induction of rRNA processing by overexpression of c-Myc or serum stimulation or 
upon starvation (Schlosser et al., 2003). The data suggest that high amounts of stalled 
RNAP I are constantly present on rDNA. Serum stimulation induces RNAP I 
elongation to harmonize 47S rRNA production with enhanced rRNA processing 
kinetics. Along the same lines, an elongation defective RNAP I mutant causes faulty 
rRNA processing and ribosome assembly, indicating that RNAP I elongation rates 
directly influence rRNA processing (Schneider et al., 2007). The creation of RNAP I 
gain of function mutants with enhanced elongation rates will help to further 
elucidate connections between RNAP I transcription and rRNA processing.  
 
 
3.3 SnoRNAs are rate limiting for 47S rRNA processing 
Searching for the subclass of RNAP II transcribed RNAs responsible for the observed 
rRNA processing defect in 3’ETS, a specific role of mRNAs and of small, Dicer-
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dependently processed RNAs was excluded first. Although prevention of mRNA 
translation and inhibition of small RNA synthesis (miRNAs) interfered with specific 
rRNA processing steps, it did not affect proper 3’ processing of the 47S rRNA. A 
number of studies suggest that Dicer and other key components of the human RISC 
pathway are implicated in rRNA processing. Knockdown of Dicer or Drosha in 
human cells blocks 5.8S rRNA maturation and leads to an accumulation of pre-5.8S 
rRNA species of various sizes (Liang and Crooke, 2011). Depletion of Drosha or 
Dicer may trigger changes in pre-rRNA secondary structures, which are 
unfavourable for processing (Wu et al., 2000; Fukuda et al., 2007; Liang and Crooke, 
2011). It has also been reported that Dicer and other RISC components are involved 
in snoRNA biogenesis. For example, ACA45 snoRNA maturation is blocked after 
Dicer knockout in mammalian cells and Giardia lamblia (Ender et al., 2008; Saraiya 
and Wang, 2008). Drosha-associated DGCR8 nuclease was found to degrade 
snoRNAs U17a, U16, and U92. (Macias et al., 2012). However, a DGCR8 knockout 
displays no rRNA processing phenotype (Wang et al., 2007). Taken together, my 
observation that Dicer1 is required for later rRNA processing steps, but not for 
nucleolar 3’ETS processing, is largely confirmed by the literature. 
 Instead, a panel of snoRNAs was found as crucial transcripts for Cdk9-
mediated rRNA processing. Almost all snoRNAs are transcribed by RNAP II, either 
as part of intronic sequences of coding genes, or as genes with their own promoter. 
While the majority of snoRNAs are not essential and mainly guide site-specific 
rRNA-modifications, a small group of snoRNAs is essential and, in addition, is 
involved in the proper endonucleolytic processing of pre-rRNA (Venema and 
Tollervey, 1999). In this context, SNORD118 (U8) deserves a particular consideration. 
U8 snoRNA is present in higher eukaryotes, but absent in yeast. U8 binds the 47S 
rRNA precursor both at the 5.8S rRNA sequence and the 28S rRNA sequence, 
guiding cleavage in the ITS-2 and, importantly, in the 3’ETS region. Depletion of U8 
in Xenopus laevis causes an inhibition of 47S rRNA processing and an accumulation of 
abnormal precursors. U8 deletion mutants indicate that the 5’ domain of U8 RNA is 
essential for its function. U8 has been suggested to function as a chaperone in long-
range folding of pre-rRNA (Peculis and Steitz, 1993; Peculis et al., 1994; Peculis, 1997; 
Michot et al., 1999). Recent studies showed that the removal of U8 snoRNA from pre-
rRNA by the helicase Ddx51 is a crucial step for the successful processing of 47S 
rRNA 3’ sequences (Srivastava et al., 2010). Ddx51 knockdown blocks 3’ETS 
processing, since U8 remains associated with unprocessed pre-rRNA. Thus, the 
reduction of U8 levels after Cdk9 inactivation may explain the observed 47S rRNA 
Discussion 
 
-58- 
processing defect. U8 is the only known snoRNA required for proper processing of 
3’ETS sequences, so far. 
 In addition, Cdk9 inactivation reduced the levels of snoRNAs U17a, U3, 
U22, and U14A. These snoRNAs are also involved in early nucleolytic cleavages of 
the rRNA precursor. U17a is required for 18S rRNA maturation (Atzorn et al., 2004). 
U3 is part of a large ribonucleoprotein complex, the small subunit (SSU) processome. 
Depletion of U3 proteins prevents 47S rRNA processing and 18S rRNA maturation 
(Beltrame and Tollervey, 1995; Dragon et al., 2002). U3 binds the 47S rRNA precursor 
at two distinct sites and cleaves in the 5’ETS region and in the ITS-1 region of the 
precursor (Beltrame and Tollervey, 1992; Kiss et al., 1991). U3 is also required for 5.8S 
rRNA maturation (Savino and Gerbi, 1990). U22 functions in 18S rRNA maturation 
(Tycowski et al., 1994). U14A complementary base pairs with the 18S rRNA and is 
required for its maturation (Dragon et al., 2002; Li et al., 1990; Hughes and Ares, 
1991; Liang and Fournier, 1995). In total, depletion of a subset of critical snoRNAs 
explains 47S rRNA stabilization after Cdk9 inactivation. In particular, depletion of 
U8 makes 3’ETS processing impossible. Lack of U17a, U3, U22, and U14A prevents 
47S rRNA cleavages in 5’ETS and ITS-1, leading to an artificial 47S rRNA precursor 
within a non-functional 90S pre-ribosome.  
 
 
3.4 A model for the regulation of ribosome biogenesis by Cdk9 
From the data discussed above I propose the following model for the function 
of Cdk9 in ribosome biogenesis. In unstressed cells, RNAP I transcription produces 
correctly processed, modified, and folded 47S rRNAs, which scaffold the assembly of 
90S pre-ribosomes (Fig. 22A). Critical snoRNAs like U3, U14A, and U8 promote the 
correct formation of rRNA secondary structures, which enable correct processing 
steps. After transcribing the termination site (T), RNAP I is paused by the 
transcription termination factor 1 (TTF-1), which is bound to an evolutionary 
conserved, tymidine-rich TTF-1 binding sequence, the Sal box (Kuhn et al., 1990; 
Jansa et al., 1998; Pfleiderer et al., 1990; Braglia et al., 2011). An unknown, but 
essential RNAse 3-like enzyme (Rnt1 in yeast) cleaves the 47S rRNA primary 
transcript in its cognate 3’ processing site, to produce the 3’ end of the 47S rRNA and 
a free 5’ end of the nascent transcript. RNAse 3-like cleavage provides an entry site 
for a 5’-3’ exonuclease (Rat1 in yeast), which degrades the RNAP I associated 
transcript, destabilizes paused RNAP I and terminates RNAP I transcription by a 
torpedo mechanism (Kufel et al., 1999; Henras et al., 2004; El Hage et al., 2008; 
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Figure 22. A model for impaired ribosome biogenesis after Cdk9 inactivation. (A) Regular ribosome 
biogenesis. Functional, Cdk9-mediated RNAP II transcription produces sufficient levels of critical snoRNAs 
like U3, U14A, and U8 for correct processing of the 47S rRNA primary transcript, which includes the 3’ETS 
formation by human homologues of yeast RNAse3 Rnt1 and 5’-3’ exonuclease Rat1 at the termination site T. 
RNAP I transcription is paused by termination factor TTF-1 at the tymidine-rich Sal box region (T-stretch). 
Normal 90S ribosomes are processed to mature ribosomal subunits, which prevents nuclolar stress. Green 
dots: rRNA cleavage sites; scissors: rRNA cleavage factors.  
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Kawauchi et al., 2008). Correct 3’ end formation and RNAP I release also requires the 
polymerase and transcript release factor PTRF, which is associated with TTF-1 and 
disassembles RNAP I from rDNA (Jansa and Grummt, 1999). The 3’ end of the 47S 
rRNA is now capable to initiate 47S rRNA processing. Sufficient amounts of U8 
snoRNA may be of particular importance for 3’ETS processing. U8 might facilitate 
initial 3’ETS processing by the correct formation of stem-loops, or the recruitment of 
downstream processing factors like endonucleases or the exosome (Peculis, 1997). 
Upon Cdk9 inactivation, RNAP II transcription is strongly impaired and critical 
snoRNAs, including U8, are no longer produced (Fig. 22B). Consequently, the 47S 
rRNA precursor lacks critical cleavage factors and secondary structures, which 
causes defective 47S rRNA processing in the 3’ETS region. Thus, the RNAse 3-like 
enzyme is no longer capable of recognizing the cleavage site and a 3’-extended 
version of 47S rRNA is stabilized. Whether the 3’-extended transcript remains 
associated with RNAP I and thereby is protected from exosomal degradation 
remains unclear. More likely, depletion of U8 causes severe structural deformations 
of the 3’ETS sequence, which prevents it from being processed. Consequently, the 
nucleolus produces misfolded, artificial 90S pre-ribosomes, which no longer can 
mature to pre-60S and pre-40S particles . 
In yeast, pre-rRNA processing occurs co-transcriptionally (Osheim et al., 
2004). To test, if co-transcriptional rRNA processing is present in human cells, I 
applied kinetic labelling experiments with 4sU. No rRNA forms were detected prior 
to the occurrence of 47S rRNA. Thus, I propose that processing of the 3’ETS sequence 
is the initial step in human rRNA processing, which is crucial for functional ribosome 
biogenesis. Defective 47S rRNA processing causes low turnover of 47S rRNA and is 
sensed by RNAP I in a negative feedback loop (Fig. 22C). Slow, but ongoing RNAP I 
transcription refills the 47S rRNA pool to regain steady state by adapting the influx 
rate to the reduced efflux rate. Accumulation of a 3’-extended 47S rRNA can be 
detected over time.  
Figure 22. (continued) (B) Ribosome biogenesis after Cdk9 inactivation. Insufficient levels of critical snoRNAs 
impair rRNA cleavages and reduce rRNA modifications and stem-loop formation. 47S rRNA is less efficiently 
processed and misfolded. This may impact on incorrect secondary structures in the 3’ETS region, which 
prevent an RNAse3-like enzyme from binding 47S rRNA, leading to a 3’-extended 47S rRNA primary 
transcript. RNAP I may read about 1 kb through the termination region. The 47S rRNA processing defect is 
sensed by transcribing RNAP I in a negative feedback loop, which slows RNAP I transcription and results in a 
non-functional, artificial 90S pre-ribosome. Defective ribosome biogenesis triggers a nucleolar stress 
response. (C) Flavopiridol inhibits 47S rRNA transcription and processing, but keeps 47S rRNA levels at 
steady state. The combination of reduced transcription and almost completely blocked processing allows the 
initially depleted 47S rRNA pool (0 min of labelling) to recover to normal levels and to accumulate over time 
(180 min of labelling), which results in 47S rRNA processing inhibition as net phenotype. FL: Flavopiridol; Tlab: 
labelling time. 
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3.5 RNAP II CTD is required for snoRNA biogenesis 
Cdk9 is a major kinase of the RNAP II CTD and phosphorylates serine-2 and 
serine-5 residues. CTD phosphorylation is a prerequisite for the recruitment of 
various cellular factors to the transcription machinery, which enables transcription of 
chromatin templates, but also correct capping, splicing, termination, and export of 
mRNAs. Recent evidence suggests that specific CTD modifications are also required 
for the controlled synthesis of snoRNAs. RNAP II CTD is methylated at a single 
arginine residue (R1810) by the arginine methyltransferase 1 (CARM1). Mutation of 
R1810 specifically enhances expression of a variety of small nuclear (sn)RNAs and 
snoRNAs, an effect that is also observed in CARM1-/- cells (Sims et al., 2011). The 
result suggests that snoRNA production is well controlled and that not each 
snoRNA-containing transcript will be processed into a mature snoRNA. Further 
evidence for a tightly regulated production of snoRNAs comes from recently 
published 4sU labelling experiments, which describe key characteristics of RNA 
processing at nucleotide resolution. The authors show that processing of most, but 
not all snoRNA-containing introns is remarkably inefficient, with the majority of 
introns being spliced and degraded rather than processed into mature snoRNAs 
(Windhager et al., 2012). But what could be the specific role of CTD phosphorylation 
by Cdk9 for snoRNA production. Although I cannot rule out a general transcription 
block of certain genes after Cdk9 knockdown, several reports described a specific 
RNA processing defect upon inhibition of Cdk9 activity. While transcription of U2 
snRNA genes and histone H2b genes does not depend on Cdk9, the activity of the 
kinase is required for recognition of the 3’ RNA processing signal of U2 snRNA by 
processing factors. Mutation of the CTD serine-2 residue causes RNAP II read-
through at the U2 snRNA 3’ end (Medlin et al., 2005). Likewise, Flavopiridol has 
been reported to reduce the accumulation of hsp70 mRNAs in Drosophila cells 
without affecting RNAP II density on the gene. Instead, a major defect was observed 
at the level of 3’ end processing (Ni et al., 2004). Similar results have been obtained 
from experiments in Xenopus laevis with the Cdk9-inhibitor DRB (Bird et al., 2004). 
Therefore, I speculate that Cdk9 regulates snoRNAs levels by post-transcriptional 
processing.  
Cdk9 inactivation impairs the expression of snoRNAs, which are transcribed 
as separate transcription units (U3 and U8) and those, which are processed from 
intron sequences of pre-mRNAs (U22, U14A, and U17a). In yeast, snoRNAs of the 
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first category terminate transcription through a pathway directed by the Nrd1 
complex, which contains the nascent RNA-binding factors Nrd1 and Nab3 as well as 
the RNA helicase Sen1 (Steinmetz et al., 2001; Thiebaut et al., 2006; Carroll et al., 
2004) (Fig. 23). Nrd1 comprises a CTD interaction domain (CID) that preferentially 
binds CTD phosphorylated at serine-5  (Gudipathi et al., 2008). Nrd1 recruitment is 
specifically enhanced at the 3’ end of genes, which is in agreement with the model 
that the Nrd1-Nab3-Sen1 termination complex acts specifically at short RNAP II 
transcribed genes (Jamonnak et al., 2011; Vasiljeva 2008). After termination, the Nrd1 
complex dissociates from the CTD to recruit the TRAMP complex and the exosome. 
TRAMP adds a short oligo-A-tail to the cleaved 3’ end, which primes for subsequent 
exosomal 3’-5’ processing (Thiebaut et al., 2006; Wlotzka et al., 2011). Nrd1-
dependent termination of non-coding RNAs is also dependent on the activity 
Figure 23. Nrd1-dependent RNAP II termination of snoRNA genes in yeast. The Nrd1-Nab3-Sen1 
complex is recruited via direct interaction between Nrd1 and the RNAP II CTD, when phosphorylated at 
serine-5. During elongation, both Nrd1 and Nab3 scan the nascent RNA for their preferred termination 
sequence. After binding to their consensus sequence, the Nrd1 complex dissociates from the CTD and 
recruits the TRAMP (Trf4/5-Air1/2-Mtr4) complex for 3’-5’ trimming of the transcript and Rat1 exonuclease for 
degradation of the remaining RNA exiting from RNAP II. Rnt1 endonulease may contribute to cleavage of 
nascent RNA (adapted from Zhang et al., 2012). 
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of the propyl isomerase Ess1. Ess1 binds the serine-2 and -5 phosphorylated CTD 
and regulates transcription by conformational isomerization of serine-proline bounds 
within the CTD. Defects in termination of snoRNAs and other small RNAs are 
observed in Ess1 mutants (Singh et al., 2009). Recent work demonstrated that CID 
point mutations of Nrd1 residues at the interface to serine-5 of the CTD diminish the 
processing of snoRNA snR13 (Kubicek et al., 2012). Together, the data suggest that 
cellular factors involved in snoRNA processing are specifically recruited to snoRNA 
genes by serine-2 and -5 dependent CTD phosphorylation marks. However, no 
human homologs of the Nrd1 complex have been identified, so far. Instead, it has 
been shown that the 3’ processing of small nuclear (sn)RNAs in mammals is 
dependent on the Integrator complex, which is recruited to serine-7 phosphorylated 
RNAP II CTD. Mutation of serine-7 causes a defect in snRNA transcription (Egloff et 
al., 2007). A possible connection between Cdk9, the Integrator, and pre-snoRNA 
processing requires further investigations. 
Correct transcription and processing of nascent pre-snoRNAs could also be a 
matter of speed. Cdk9 promotes RNAP II elongation not only via CTD 
phosphorylation, but also by phosphorylation of Spt4/5 and NELF. Cdk9 
inactivation may reduce the capability of RNAP II to transcribe through chromatin, 
in case Spt4/5 and NELF lack critical modifications, remain with RNAP II, and fail to 
recruit elongation factors like the Paf1 complex. Reduced elongation may contribute 
to reduced co-transcriptional processing of pre-snoRNAs, as shown for alternative 
splicing that depends on the elongation rate (de la Mata et al., 2003). Maturation of 
pre-snoRNA sequences and their association with binding proteins to form snoRNP 
complexes requires functional pre-mRNA splicing and involves the Hsp90 co-
chaperone complex R2TP and the nuclear assembly factor 1 (Naf1) (see Fig. 6 for 
details). Depletion of Hsp90 and R2TP components inhibits snoRNP maturation, 
reduces box C/D snoRNAs and blocks rRNA processing (Zhao et al., 2008; Boulon et 
al., 2008). Interestingly, Naf1 has been shown to bind phosphorylated RNAP II CTD 
(Richard et al., 2006; Fatica and Tollervey, 2002). Taken together, several additive 
mechanisms may contribute to the strong depletion of snoRNAs.  
 
 
3.6 Differential regulation of rRNA synthesis by Ctk1 and Bur1/2  
Depletion of the yeast Cdk9 homolog Bur1/2 specifically inhibited later rRNA 
processing, but had no impact on production of 35S rRNA. In contrast, Ctk1 blocked 
35S rRNA transcription and its maturation to 25S and 18S rRNA. How can these 
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phenotypes be explained and why do they differ? Bur1/2 and Ctk1 have well-known 
functions in RNAP II transcription. Both kinases are critical for RNAP II elongation. 
Both kinases phosphorylate the RNAP II CTD at position serine-2, Bur1/2 also 
phosphorylates the negative elongation factor Spt4/5 (Cho et al., 2001; Zhou et al., 
2009; Keogh et al., 2003). Spt4/5 is highly conserved and can close the DNA clamp of 
RNAP II, enabling processive elongation (Martinez-Rucobo et al., 2011; Hartzog et 
al., 1998). Recent studies suggest that Ctk1 and Spt4/5 functions also impact on 
RNAP I transcription and rRNA processing. Dual functions make interpretation of 
phenotypes difficult, since an effect via RNAP II transcription is difficult to exclude. 
Ctk1 partially localizes in the nucleolus and interacts directly with RNAP I to foster 
rRNA transcription initiation. Depletion of Ctk1 inhibits RNAP I, decreases the 
number of rDNA repeats and causes nucleolar disruption (Bouchoux et al., 2004; 
Grenetier et al., 2006). Consequently, I find rRNA transcription reduced after 
depletion of Ctk1, but fully functional after Bur1/2 depletion, which, in turn, inhibits 
rRNA processing. Spt4/5 function may explain this phenotype. Mutations in Spt4/5 
decrease rDNA copy numbers and lead to an rRNA processing defect, which closely 
resembles inhibition of 27S rRNA processing after Bur1/2 depletion (Schneider et al., 
2006). Spt4/5 has been shown to associate with rDNA in vivo and interact with 
RNAP I (Leporé and Lafontaine, 2011). Non-phosphorylated Spt4/5 pauses RNAP I 
before elongation (Schneider et al., 2006; Anderson et al., 2011). Upon 
phosphorylation, Spt4/5 recruits the Paf1 complex, which is crucial for efficient 
transcription elongation through chromatin (Zhang et al., 2009; Zhang et al., 2010). I 
assume that both Spt4/5 mutation and Bur1/2 depletion impair Paf1 recruitment to 
RNAP I and thereby impair elongation. Based on similarities to RNAP II elongation, 
Bur1/2 might modulate Spt4/5 activity to regulate RNAP I elongation and co-
transcriptional rRNA processing. 
One could also speculate that Ctk1 and Bur1/2 orchestrate the expression of 
different subsets of genes, which are, for example, required for different steps in 
ribosome biogenesis. While Ctk1 primarily supports transcription of rRNA, Bur1/2 
may preferentially promote the expression of factors required for rRNA processing. 
Bur1/2 depletion may cause an imbalance in the synthesis of non-coding RNAs, 
required for rRNA processing, but not transcription, which might at least partially 
explain the Bur1/2-mediated inhibition of 27S rRNA processing. Bur1/2 depletion 
could also interfere with premature cleavage (PMC). It has been shown that co-
transcriptional premature cleavage in the ITS-1 produces up to 70 % of immature 27S 
rRNA in yeast under growth favourable conditions (Kos and Tollervey, 2010). 
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Reduced PMC could explain the observed accumulation of 35S rRNA, which could 
no longer be processed adequately into 25S rRNA upon depletion of Bur1/2-
dependent early rRNA processing factors. The different contributions of Ctk1 and 
Bur1/2 to the regulation of gene expression are subject of current research (Wood 
and Shilatifard, 2006). 
 
After having shed light on the molecular mechanism of Cdk9-mediated rRNA 
processing, the focus will now be on the nucleolar stress response, which is induced 
upon rRNA processing inhibition and connects ribosome biogenesis to cell cycle 
control.  
 
 
3.7 Defective rRNA processing triggers nucleolar stress  
The existence of an interphase nucleolus is dependent on the constant 
production of pre-rRNA, to balance the loss of rRNA from the nucleolus by 
maturation of pre-rRNA. Nucleolar stress abrogates pre-rRNA synthesis. This 
imbalance causes translocation of nucleolar factors like NPM1 into the nucleoplasm. 
Consequently, the nucleolar structure collapses and disintegrates into substructures 
(Hernandez-Verdun et al., 2010). Nucleoplasmatic NPM1 localization was used as a 
marker for nucleolar disruption after Cdk9 knockdown. NPM1 relocates to the 
nucleolus upon stress relief (Chan et al., 1996). NPM1 translocation to the 
nucleoplasm is accompanied by p53 stabilization. Importantly, p53 induction differs 
from the classical DNA damage response, which involves Ataxia telangiectasia 
mutated kinase (ATM), checkpoint kinase 1 (CHK1), and phosphorylation of p53 at 
position serine-15. Active p53 induces cell cycle inhibitors like p21Cip and p27Cip, 
which negatively regulate Cdk2 activity and arrest the cell cycle in G1-phase (Lane, 
1992; Levine, 1997; Sakaguchi et al., 1998; Ljungman, 2000; Harper et al., 1995; 
Vogelstein et al., 2000). Remarkably, p53 serine-15 phosphorylation is absent after 
nucleolar stress, suggesting alternative pathways to active p53 (Hölzel et al., 2010a). 
Recent studies revealed that the levels rather than modifications of p53 are crucial for 
its activity. p53 modifications rather fine-tune its activity (Blattner et al., 1999; Efeyan 
et al., 2006). The nucleolar stress-mediated p53 response is superior to DNA-damage 
signalling, since it induces p53 by all means and independently of functional kinases. 
Consequently, Cdk9 knockdown reduced cell proliferation. Ongoing proliferation 
directly after onset of nucleolar stress indicates that NPM1 translocation, and p53 
induction precedes inhibition of proliferation. Taken together, the data support the 
Discussion 
 
-66- 
current view that inhibition of ribosome biogenesis is the cause and not a 
consequence of p53-mediated cell cycle arrest. 
High concentrations of 4sU globally inhibited rRNA synthesis and induced 
nucleolar stress. The molecular details of the nucleolar stress phenotype have been 
discussed above. Interestingly, the inhibition of rRNA synthesis by 4sU differed from 
5-FU, which specifically blocks 32S rRNA processing (Ghoshal and Jacob, 1994; 
Burger et al., 2010). How can this difference be explained? Both drugs are uridine 
analogs, but are modified at different positions, resulting in different structures. Both 
4sU and 5-FU can be incorporated at potential target sites for pseudouridylation. 
Incorporation of 5-FU at such target site has been reported. Incorporation of 5-FU 
into U2 small nuclear (sn)RNA prevents pseudouridylation and formation of 
functional snRNPs for pre-mRNA splicing (Zhao and Yu, 2007). In analogy, 
inhibition of 32S rRNA processing by 5-FU could be explained by its incorporation 
into rRNA and/or snoRNAs, and the lack of critical pseudouridylations. Taken 
together, 4sU impairs rRNA synthesis and potentially changes the secondary 
structure and function of mature 28S, 5.8S and 18S rRNA within the ribosome. It is 
tempting to speculate, if 4sU allows correct formation of fully functional ribosomes.  
4sU-tagging of nascent RNA is a sophisticated approach to measure 
transcription, processing, and turnover of newly transcribed RNA (Dölken et al., 
2008; Friedel et al., 2009; Rabani et al., 2011; Windhager et al., 2012). Data from this 
thesis underscore that metabolic labelling of RNA with 4sU is a feasible approach. 
However, labelling time and 4sU concentration should be kept as short as possible, 
with regard to the severe nucleolar stress 4sU can cause.  
 
 
3.8 Defects in ribosome biogenesis are the origin of multiple diseases 
Mutations of single ribosomal proteins and processing factors cause a number 
of haematological diseases, so called ribosomopathies. Mutations in ribosomal 
proteins S19, L5, L11, S24, L35a, S17, or S7 cause Diamond-Blackfan anemia (DBA) 
and an increased susceptibility to haematological malignancies (Narla and Ebert, 
2010). S19 is the most prominent driver of DBA. Mutations in S19 and S24 impair 18S 
rRNA maturation and 40S subunit formation (Draptchinskaia et al., 1999; Hölzel et 
al., 2010a; Choesmel et al., 2007, Flygare et al., 2007). A point mutation in ribosomal 
protein S14 causes the 5q--syndrome, an independent subtype of the myelodysplastic 
syndrome, which includes macrocytic anaemia. S14 haploinsufficiency impairs 18S 
rRNA maturation and 40S subunit formation (Ebert et al., 2008). p53 triggers a 5q--
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syndrome phenotype in a S14 knockout mouse (Barlow et al., 2010). Mutations in the 
SBDS gene cause the Schwachman-Diamond syndrome (SDS), which includes 
ineffective haematopoiesis and an increased risk to develop leukaemia. SBDS is 
required for rRNA processing and 60S subunit formation. SBDS also catalyzes 
translation initiation by stimulating ribosomal subunit joining (Boocock et al., 2003; 
Ganapathi et al., 2007; Finch et al., 2011). Dyskerin (DKC1) is the pseudouridine 
synthase, which complexes in box H/ACA snoRNPs and catalyzes the 
pseudouridine rRNA modification. Mutations in DKC1 are associated with 
Dyskeratosis congenita, reduce rRNA pseudouridylation, induce defective rRNA 
processing in mice, and cause bone marrow failure (Lafontaine et al., 1998; Dokal, 
2000; Ruggero et al., 2003). A number of additional diseases are caused by 
dysfunctional ribosomes (Narla and Ebert, 2010). 
It is not entirely clear, how mutations in ribosome biogenesis factors, present 
in each cell, can cause specific haematological diseases or malignancies restricted to 
particular tissues. p53 stabilization and induction of cell cycle arrest and apoptosis 
are common features of ribosomopathies (McGowan et al., 2008; Fumagalli et al., 
2009). Apoptosis might shatter the erythroid/myeoloid lineage more severe than the 
lymphoid lineage, which may cause an imbalance in the haematological system.  
Breast cancer cells not only produce higher amounts of ribosomes, but also 
ribosomes of a different quality. Ribosomes in breast cancer are synthesized by 
alternative rRNA processing pathways, which leads to the accumulation of unusual 
pre-rRNA forms. These so called ‘cancer ribosomes’ have different rRNA 
modification patterns and altered translational capacities. In fact, rRNA in ‘cancer 
ribosomes’ carries additional and novel methylation sites (Belin et al., 2009). Changes 
in the rRNA modification pattern are thought to decrease translational fidelity, 
induce misfolding of rRNA and reduce internal ribosome entry site (IRES)-
dependent translation. Given that the expression of many tumor suppressors like p27 
or p58 relies on IRES-dependent translation, ‘cancer ribosomes’ may be of direct 
relevance for transformation (Kullmann et al., 2002; Cornelis et al., 2000; Vagner et 
al., 2001; Silvera et al., 2010). One could speculate that snoRNA-guided rRNA 
modification patterns differ in ‘cancer ribosomes’ or among tissues. Distinct, tissue-
specific rRNA modification signatures may exist, that regulate translation of key cell 
cycle regulating factors. Alternatively, defective ribosomal subunits could diminish 
translation of globin genes, which leads to a relative excess of free heme and could 
trigger erythroid specific apoptosis and anaemia (Keel et al., 2008). Other models rely 
on possible extraribosomal functions of several ribosomal proteins. Mutations in 
Discussion 
 
-68- 
ribosomal proteins may alter DNA replication or DNA repair, too (Warner and 
McIntosh, 2009).  
A number of options to interfere with snoRNA biogenesis and rRNA synthesis 
have been defined, recently. For example, the Hsp90 chaperone inhibitor 
Geldanamycin prevents snoRNP assembly on nascent snoRNAs by impairing the 
correct folding of snoRNP stabilizing proteins like Nop56, Nop58, or Fibrillarin. 
Unprotected snoRNAs are rapidly degraded and rRNA processing is inhibited 
(Boulon et al., 2008). Since Hsp90 is overexpressed in many tumors, Geldanamycin is 
a promising drug for treatment of cancer. However, inhibition of protein folding may 
have global impact on many cellular processes (Pearl and Prodromou, 2006; Caplan 
et al., 2007). Inhibition of pre-mRNA splicing is an alternative approach to interfere 
with snoRNA biogenesis. The biogenesis of snoRNAs is actively coupled with 
splicing. The natural product Isoginkgetin, for example, is a general inhibitor of 
splicing; it prevents the recruitment of spliceosomal snRNP subunits U4/U5/U6 
(O’Brien et al., 2008). Isoginkgetin is a known anti-tumor drug (Yoon et al., 2006). 
Similarly, Spliceostatin A and Pladienolide B also impair pre-mRNA splicing. Both 
substances bind and inactivate SF3b, a subcomplex of the U2 snRNP to prevent 
spliceosome assembly (Kaida et al., 2007). Unfortunately, inhibition of splicing may 
also globally interfere with pre-mRNA synthesis. In 2011, Drygin and colleagues 
have reported a more direct approach to inhibit rRNA synthesis. They found that the 
small molecule CX-5461 is a selective inhibitor of RNAP I transcription initiation that 
specifically blocks recruitment of the SL1 complex and impairs PIC formation. The 
anti-tumor activity is conferred by p53 stabilization. CX-5461 is effective in human 
solid tumors; its therapeutic potential is currently tested in clinical trials. Taken 
together, these examples show that ribosome biogenesis is an emerging field in 
cancer research. Exciting recent findings led to a number of models and 
hypothesises, to elucidate the intimate connection between ribosome biogenesis 
regulation and its deregulation in cancer.  
Cdk9 is no classical proto-oncogene. However, Cdk9 mRNA levels are 
specifically elevated in Acute Myeloid Leukaemia (AML) and in Acute Lymphoid 
Leukemia (ALL) (www.genesapiens.org). Tumor growth is often driven by 
hyperactivation of kinases. Cdk9 mutations could hind to alterations in RNAP II 
transcription, snoRNA biogenesis, or ribosome biogenesis. Specific Cdk9-inhibitors 
might be of particular interest in the therapy of haematological diseases. However, 
no mutations in Cdk9 have been found in the AML genome, so far (Mardis et al., 
2009; Greif et al., 2011). Why is Cdk9 unregulated in AML/ALL? Are AML/ALL 
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cells hyposensitive to FL treatment? Further investigations are necessary to clarify, 
whether elevated Cdk9 expression could be directly connected to rRNA processing 
and may contribute to the onset of haematologic diseases.   
 
 
3.9 Outlook 
This thesis contributes to the establishment of ribosome biogenesis as a Cdk9-
dependent process with possible therapeutic relevance. Cdk9 inactivation is a 
powerful approach that abrogates snoRNA biogenesis, causes defective 47S rRNA 
processing, and induces nucleolar stress. Given that pre-mRNA splicing and 
snoRNA synthesis are coupled events and depend on Cdk9-mediated RNAP II 
transcription elongation, one could imagine that mutations in the CTD or alterations 
of its modification pattern may influence snoRNP biogenesis by the abrogation of 
proper Nrd1-mediated 3’ processing, but also by preventing the function of CTD-
associated snoRNP assembly factors, like R2TP or Naf1. It will be interesting to find 
out, whether the association of Naf1 or R2TP to the CTD is altered after changes of 
the CTD modification pattern, as demonstrated for Nrd1 termination factor (Kubicek 
et al., 2012). This might further point towards a direct regulation of snoRNA 
biogenesis by RNAP II. Deregulation of snoRNA biogenesis alters the rRNA 
modification status quantitatively and qualitatively. Alterations in Cdk9-mediated 
RNAP II transcription may lead to changes of rRNA modification patterns, cause 
misfolding of the ribosome, and reduce its translational fidelity. It will be exciting to 
investigate the contribution of RNAP II transcription and snoRNA biogenesis to the 
formation of rRNA modifications patterns and translation in ‘cancer ribosomes’ or 
among tissues and may help to further understand the connection between defective 
ribosome biogenesis and the onset of ribosomopathies.  
Apart from modulating RNAP II transcription, the possibility that Cdk9 
phosphorylates additional nucleolar substrate(s) cannot be excluded. The knockout 
of the yeast Cdk9 homolog Ctk1 alters the phosphorylation patterns of several 
nucleolar proteins, most prominently of the yeast pseudouridine synthase Cbf5 
(SILAC screen by Dr. Katja Strässer, unpublished results). Although Cbf5 could not 
be confirmed as a direct substrate of Ctk1 in an in vitro kinase assay, it will be 
interesting to analyze, whether Ctk1 or Bur1/2 can phosphorylate components of the 
snoRNA biogenesis machinery such as Nrd1, Naf1, R2TP complex, or snoRNP 
proteins.  
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In the course of investigating Cdk9-dependent 47S rRNA processing, I found 
that Cdk9 is specifically required for the processing of the 3’ETS sequence within the 
47S rRNA. Cdk9 inactivation stabilizes a 3’-extended 47S primary transcript 
accompanied by reduced RNAP I transcription. Does the 3’-extended primary 
transcript remain associated with RNAP I and is thereby protected from 
polyadenylation and exosomal degradation? Is Cdk9 involved in RNAP I 
termination? Is there a failsafe termination mechanism existing as demonstrated in 
yeast? Unanswerd questions leave room for further investigations. 
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4. MATERIALS 
 
 
 
 
 
4.1 Reagents 
(4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid (HEPES) MP Biomedicals Inc., Eschwege 
[32P]-ortho-phosphate (32P) Hartmann-Analytik, Braunschweig 
[!-32P]-Desoxyadenosine Triphosphate (!-32P-dATP), 6000 
µCi/mmol Hartmann-Analytik, Braunschweig 
1,4-Dithiothreitol (DTT) Carl Roth GmbH&CoKG, Karlsruhe 
1 kb DNA ladder Invitrogen, Karlsruhe 
3-(N-Morpholino)-propanesulfonic Acid (MOPS) Sigma-Aldrich Chemie, GmbH, Deisenhofen 
4'-6-Diamino-2-phenylindole (DAPI) Sigma-Aldrich Chemie, GmbH, Deisenhofen 
4-Thiouridine (4sU) Sigma-Aldrich Chemie GmbH, Deisenhofen 
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) Sigma-Aldrich Chemie GmbH, Deisenhofen 
5-Fluorouracil (5-FU) Sigma-Aldrich Chemie GmbH, Deisenhofen 
5 x First Strand Buffer Invitrogen, Karlsruhe 
Acetate (Ac) Carl Roth GmbH&CoKG, Karlsruhe 
Actinomycin D (ActD) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Agarose, Ultra Pure Invitrogen, Karlsruhe 
Albumin Fraction V (BSA) Carl Roth GmbH&CoKG, Karlsruhe 
#-Amanitin (#-Am) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ammonium Hydroxide (NH4OH) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Ammonium Persulfate (APS) Carl Roth GmbH&CoKG, Karlsruhe 
Amplify Solution GE-Healthcare, München 
Anisomycin (AIM) Sigma-Aldrich Chemie GmbH, Deisenhofen 
$-Mercaptoethanol ($-ME) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Biotin-HPDP Pierce, Rockford, USA 
Bromophenol Blue (BPB) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Cdk1-inhibitor CGP74514A Merck, Darmstadt 
Cdk2-inhibitor Compound 3 CalBioChem 
Cdk9-inhibitor II CalBioChem 
Cdk9-inhibitor KM05283SC Maybridge, Cornwall 
Cdk13-inhibitor TG003 Tocris Bioscience, Ellisville 
Chloroform Carl Roth GmbH&CoKG, Karlsruhe 
Cycloheximide (CHX) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Desoxyribonucleosidetriphosphate mix (dNTPs) Promega, Mannheim 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Dimethyl Formamide (DMF) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Disodium Hydrogen Phosphate (Na2H2PO4) Merck KGaA, Darmstadt 
Dulbecco's Modified Eagle Medium (DMEM) Invitrogen, Karlsruhe 
Dulbecco's Modified Eagle Medium, Phosphate-free (DMEM-P) Invitrogen, Karlsruhe 
Ethanol (EtOH), absolut Merck, Darmstadt 
Ethidium Bromide (EtBr) Fluka Chemie GmbH, Buchs 
Ethylenediaminetetraacetic Acid (EDTA) Carl Roth GmbH&CoKG, Karlsruhe 
Fetal Bovine Serum (FBS) PAA Laboratories, Pasching, Österreich 
Fetal Bovine Serum, dialyzed, Phosphate-free (FBS-P) Invitrogen, Karlsruhe 
Flavopiridol (FL) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Fluorescent Mounting Medium, Vecta Shield Dako GmbH, Hamburg 
Formaldehyde (37 %) Carl Roth GmbH&CoKG, Karlsruhe 
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Formamide Sigma-Aldrich Chemie GmbH, Deisenhofen 
Galactose Merck, Darmstadt 
Glucose Merck, Darmstadt 
Glycerol 86 % Carl Roth GmbH&CoKG, Karlsruhe 
Glycine Carl Roth GmbH&CoKG, Karlsruhe 
Homoharringtonine (HHT) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Hydrogen Chloride (HCl) Merck, Darmstadt 
Hygromycin B (Hyg) Invitrogen, Karlsruhe 
Immersol 518F Carl Zeiss AG, Oberkochem 
Isopropanol, absolut Carl Roth, Karlsruhe 
Kalium Acetate (KAc) Merck KGaA, Darmstadt 
Kalium Chloride (KCl) Merck KGaA, Darmstadt 
Kalium Dihydrogen Phosphate (KaH2PO4) Merck KGaA, Darmstadt 
Kalium Hydroxide (KOH) Merck KGaA, Darmstadt 
L-Glutamine 200mM (100 x) Gibco BRL Life Technologies, Eggenstein 
Magnesium Chloride (MgCl2) Merck KGaA, Darmstadt 
Magnesium Sulfate (MgSO4) Merck KGaA, Darmstadt 
Methanol (MeOH), absolut Merck KGaA, Darmstadt 
Methotrexate (MTX) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Oligofectamine Invitrogen, Karlsruhe 
OptiMEM Invitrogen, Karlsruhe 
Orange G Sigma-Aldrich Chemie GmbH, Deisenhofen 
Paraformaldehyde (PFA) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Peniciline/Streptomycin (100x) Invitrogen, Karlsruhe 
Phenylmethanesulfonyl Fluoride (PMSF) ICN Biomedicals Inc., Fountain Pkwy, USA 
Piperazine-N-N'-bis(2-ethanesulfonic Acide (PIPES) ICN Biomedicals Inc., Fountain Pkwy, USA 
Polyacrylamide 30 % (PAA) Carl Roth GmbH&CoKG, Karlsruhe 
Powdered Milk, blotting grade Carl Roth GmbH&CoKG, Karlsruhe 
Prestained Protein Ladder Plus Fermentas, St. Leon-Rot 
Puromycin (PM) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Random Hexamer Primer (0.2 µg/µl) Fermentas, St. Leon-Rot 
RNAsin Rnase-inhibitor Promega, Mannheim 
Roscovitine Sigma-Aldrich Chemie GmbH, Deisenhofen 
Roswell Park Memorial Institute Medium (RPMI) 1640 Invitrogen, Karlsruhe 
Select Peptone Merck, Darmstadt 
Sodium Acetate (NaAc) Merck KGaA, Darmstadt 
Sodium Azide (NaN3) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Sodium Chloride (NaCl) Merck KGaA, Darmstadt 
Sodium Citrate Merck KGaA, Darmstadt 
Sodium Dodecyl Sulfate (SDS) Carl Roth, Karlsruhe 
Sodium Hydrogen Phosphate (NaH3PO4) Merck KGaA, Darmstadt 
Sodium Hydroxide (NaOH) Merck KGaA, Darmstadt 
Sorbitol Merck KGaA, Darmstadt 
Sucrose ICN, Northeim 
Superscript Reverse Transcriptase II Invitrogen, Karlsruhe 
T4-Polynucleotide Kinase (PNK) New England Biolabs, Ipswich 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH&CoKG, Karlsruhe 
Tris(hydroxymethyl)aminoethane (TRIS) Carl Roth GmbH&CoKG, Karlsruhe 
Triton-X-100 Sigma-Aldrich Chemie GmbH, Deisenhofen 
Tryphan Blue Invitrogen, Karlsruhe 
Trypsin-EDTA (0.5 %) Gibco BRL Life Technologies, Eggenstein 
Tween-20 Carl Roth GmbH&CoKG, Karlsruhe 
Uridine (Uri) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Xylene Cyanole Sigma-Aldrich Chemie GmbH, Deisenhofen 
Yeast Extract Merck, Darmstadt 
Zymolyase 20T MP Biomedicals Inc., Eschwege 
 
 
4.2 Consumables and kits 
Amersham hyperfilm ECL GE Healthcare, München 
Amersham hyperfilm MP GE Healthcare, München 
Cell Scraper Sarsted, Newton 
Cover Slides Menzel, Braunschweig 
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Cyrovials 1.5 ml Nunc GmbH, Wiesbaden 
ECL kit GE Healthcare, München 
Gel Blotting Paper GB003 Schleicher & Schuell, Deutschland 
Hybond N+ Nylon Membrane GE Healthcare, München 
Hybond-ECL Nitrocellulose Membrane GE Healthcare, München 
Laboratory Glassware Duran Productions GmbH & Co. KG, Mainz 
Light Cycler Capillaries Roche Chemicals, Mannheim 
Light Cycler FastStart DNA Master SYBR Green I Roche Chemicals, Mannheim 
Micro Slides Karl Hecht KG, Sondheim 
MicroSpin S-200HR Columns GE-Healthcare, München 
µMACS Streptavidin kit Miltenyi, Bergisch-Gladbach 
Nail Polish Manhatten Base Coat 
Nitrile Gloves Kimberly-Clark, Koblenz 
Pasteur Pipettes Hirschmann Laborgeräte, Eberstadt 
Pipette Tips ART 10, 20, 200, 1000) MolecularBio-Products, San Diego 
Plastic ware for cell culture Greiner Bio-One,Frickenhausen 
Phase Trap Gel Heavy Tubes PeqLab Biotechnologie GmbH, Erlangen 
PVDC Saran Foil Dow, Midland 
Reaction Tubes 1.5 ml, 2 ml Eppendorf, Hamburg 
Reaction Tubes 15 ml, 50 ml Becton Dickinson Biosiences, Heidelberg 
Scalpel Braun, Tuttlingen 
Total RNA kit PeqGOLD PeqLab Biotechnologie GmbH, Erlangen 
Whatman Paper Whatman, London 
 
 
4.3 Equipment 
Axiovert 200M Fluorescence Microscope Carl Zeiss Jena GmbH, Göttingen 
BAS Imaging Plate Fujifilm, Düsseldorf 
Biofuge 13 Heraeus Sepatech GmbH, Osterode 
BioPhotometer Eppendorf-Netheler-Hinz GmbH, Hamburg 
Blotting chamber Bio-Rad Laboratories GmbH, München 
Branson Sonifier 250 Heinemann Ultraschall- und Labortechnik  
Cawomat 2000 IR developer CAWO GmbH, Schrobenhausen 
Combi-printer PIXMA MP510 Canon GmbH, Krefeld 
Electrophoresis equipment Bio-Rad Laboratories GmbH, München 
Eppendorf Centrifuge 5417R Eppendorf, Hamburg 
Eraser Raytest GmbH, Straubenhardt 
FLA-5100 PhosphorImager  Fujifilm, Düsseldorf 
Fridge KU 171 Liebherr, Biberach 
Freezer Siemens, München 
Fuchs-Rosentahl chamber GLW Gesellschaft für Laborbedarf GmbH 
Gel dryer 543 Bio-Rad Laboratories GmbH, München 
Gilson Pipettes 2,10,20,200,1000 Gilson, Bad Camberg 
GS Gene Linker UV Chamber Bio-Rad Laboratories GmbH, München 
Hybaid hybridising machine Binder, Tuttlingen 
Hypercassette GE Healthcare, München 
Inkubator Heraeus 6000 Heraeus Sepatech GmbbH, Osterode 
Kyowaglass Kurary Co., Japan 
Label counter, scintillation detector, QC-4000 Bioscan, Washington, DC 
Laminar Flow Hood BDK GmbH, Sonnenbühl 
LB122 Berthold ($-, !-detection)  Berthold Technologies, Bad Wildbad 
Light cycler 2.0 Rcohe Diagnostics, Penzberg 
Magnet stirer M23 GLW, Würzburg 
Magnetic Stand OctoMACS Seperator Miltenyi, Bergisch-Gladbach 
Megafuge 2.0 Heraeus Sepatech GmbH, Osterode 
Microwave Panasonic, Hamburg 
Multi-calimatic pH-meter Knick GmbH & Co. KG, Berlin 
Multichannel pipette 50M PeqLab Biotechnologie GmbH, Erlangen 
Nanodrop 1000 Thermo Scientific, Braunschweig 
PipetMan P Gilson, Bad Camberg 
PowerPack Bio-Rad Laboratories GmbH, München 
Rollermixer SRT 2  Dunn GmbH, Augsburg 
SDS-PAGE gel tank Amersham Pharmacia Biotech, Freiburg 
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Telaval 31 microscope Carl Zeiss Jena GmbH, Göttingen 
Thermal printer P91 Mitsubishi, Japan 
Thermomixer 5436 Eppendorf-Netheler-Hinz GmbH, Hamburg 
UV lamp VL-4. LC PeqLab Biotechnologie GmbH, Erlangen 
Vacuum pump  Vacuumbrand GmBH & CoKG, Tuttlingen 
Vortex Genie II GLW, Würzburg 
Wet chamber self-made 
xCELLigence E-Plate 16 Roche Diagnostics, Penzberg 
xCELLigence Real-Time Cell Analyzer (RTCA) DP Roche Diagnostics, Penzberg 
 
 
4.4 Software 
AIDA Version 3.20.116 Raytest GmbH, Straubenhardt 
Canon MP Navigator 3.0.0 Canon GmbH, Krefeld 
ImageJ 1.34s Wayne Rasband, Maryland 
Microsoft Office 2005, 2008, 2011 Microsoft, Washington, DC 
Openlab demo 3.0.8 Improvision, Coventry 
 
 
4.5 Buffers and solutions 
1 % Agarose-Formaldehyde-Gel for RNA 4 g Agarose 
 300 ml ddH2O 
 boil in microwave 
 cool to 65°C 
 40 ml MOPS-Buffer (10 x) 
 67 ml Formaldehyde (37 %) 
  
2 % Agarose-TAE-Gel for DNA 4 g Agarose 
 400 ml 1x TAE 
 boil in microwave 
 cool to 65°C 
 add EtBr (375 ng/µl) 
  
Antibody Stock Solution 5 % BSA in TBST 
 add NaN3 
  
10 x Biotinylation Buffer 100 mM Tris pH 7.4 
 10 mM EDTA 
  
Church Buffer (1 L) 400 ml 1 M Na2HPO4 
 100 ml 1 M  NaH2PO4 
 adjust pH to 7.1 
 350 ml 20 % SDS 
 2 ml 0.5 M EDTA 
 ad 1 L H2O 
  
DEPC-H2O 0.1 % DEPC in H2O 
 incubate at 37°C over night 
 autoclave 
  
10 x DNA Loading Dye 20 g Sucrose 
 100 mg Orange G 
 ad 50 ml H2O 
  
DAPI Stain Solution 0.025 % (m/v) DAPI in 1 x PBS 
  
FBS Antibody Solution 0.15 % FBS in 1 x PBS 
  
FBS Blocking Solution 10 % FBS in 1 x PBS 
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2 x Lämmli Buffer 2 % SDS 
 100 mM DTT 
 10 mM EDTA 
 10 % Glycerol 
 60 mM Tris/HCl pH 6.8 
 0.01 % BPB 
 1 mM PMSF 
  
Milk powder solution 5 % powdered milk in 1 x TBST 
  
1 x µMACS Washing Buffer 100 mM Tris pH 7.5 
 10 mM EDTA 
 1 M NaCl 
 0.1 % Tween-20 
  
10 x MOPS-Buffer pH 7.0 20 mM MOPS 
 50 mM NaAc (H2O-free) 
 1 mM EDTA 
  
1 x MOPS Running Buffer 300 ml 10 x MOPS Buffer 
 ad 3 L H2O 
  
1 x PBS (pH 7.2-7.4) 137 mM NaCl 
 2.7 mM KCl 
 4.3 mM Na2HPO4*6H2O 
 1.4 mM KH2PO4 
  
0.04 % Triton-X-100 (PBST) 0.04 % (v/v) Trition-X-100 in 1 x PBS 
  
2 x RNA Loading Dye 5 ml Formamide 
 1.5 ml Formaldehyde 
 1 ml 10 x MOPS Buffer 
 1 ml BPB (1 %) 
 10 µl EtBr (10 mg/ml) 
 1.5 ml DEPC-H2O 
  
S-Buffer 1 M Sorbitol 
 10 mM PIPES 
 adjust pH to 6.5 
  
10 x SDS Running Buffer 30,24 g Tris Base 
 144 g Glycine 
 50 ml 20 % SDS 
 ad 1 L H2O 
  
SDS-PAGE Stacking Gel (4 %) 2 ml 30 % PAA 
 7.5 ml 2 x Tris/SDS pH 6.8 
 5.4 ml H2O 
 90 µl APS 
 20 µl TEMED 
  
SDS-PAGE Separating Gel (10.5 %) 7 ml 30 % PAA 
 10 ml 2 x Tris/SDS pH 8.8 
 0.5 ml H2O 
 167 µl APS 
 17 µl TEMED 
  
20 x SSC Buffer 3 M NaCl 
 0.3 M Sodium Citrate 
 pH 7.0 
  
0.1 x SSC Wash Buffer (500 ml) 2.5 ml 20 x SSC (0.1 x) 
 12.5 ml 20 % SDS (0.5 %) 
 ad 500 ml H2O 
  
2 x SSC Wash Buffer (500 ml) 50 ml 20 x SSC (2 x) 
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 25 ml 20 % SDS (1 %) 
 ad 500 ml H2O 
  
1 x TAE Buffer 40 mM Tris Acetate 
 1 mM EDTA 
 adjust pH to 8.0 
  
10 x TBS Buffer 100 mM NaCl 
 10 mM Tris/HCl pH 7.5 
  
10 x TBS-Tween (TBST) 1 % Tween-20 in TBS 
  
10 x Transfer Buffer 30,24 g Tris Base 
 144 g Glycine 
 50 ml 20 % SDS 
 200 ml MeOH 
 ad 1 L H2O 
  
1 x Tris/EDTA (TE) pH 8.0 10 mM Tris 
 1 mM EDTA 
 adjust pH to 8.0 
  
2 x Tris/SDS pH 6.8 30.24 g Tris Base 
 10 ml 20 % SDS 
 ad 1 L H2O 
 adjust pH to 6.8 
  
2 x Tris/SDS pH 8.8 90,72 g Tris Base 
 10 ml 20 % SDS 
 ad 1 L H2O 
 adjust pH to 8.8 
 
 
4.6 Media 
Depletion Medium 10 % FBS, dialyzed in DMEM-P 
  
DMEM complete 89 % DMEM 
 9 % FBS 
 1 % L-Glutamine (200 mM) (100 x) 
 1 % Peniciline/Streptomycin (100 x) 
  
Freeze Medium 90 % FBS 
 10 % DMSO 
  
Pulse Medium 10 % FBS, dialyzed in DMEM-P 
 15 µCi/ml [32P]-ortho-phosphate 
  
RPMI complete 89 % RPMI 
 9 % FBS 
 1 % L-Glutamine (200 mM) (100 x) 
 1 % Peniciline/Streptomycin (100 x) 
  
Thaw Medium 80 % DMEM 
 20 % FBS 
  
Yeast Complete Galactose Medium (YPG) 20 g Select Peptone 
 10 g Yeast Extract 
 935 ml H20 
 autoclave 
 add 2 % Galactose 
  
Yeast Complete Glucose Medium (YPD) 20 g Select Peptone 
 10 g Yeast Extract 
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 935 ml H20 
 autoclave 
 add 2 % Glucose 
  
Phosphate-free Yeast Depletion Medium 20 g Select Peptone 
 10 g Yeast Extract 
 935 ml H20 
 10 ml 1 M MgSO4 
 10 ml aqueous NH4OH 
 remove precipitated phosphate by filtration 
 adjust to pH 5.8 
 autoclave 
 add 2 % Glucose 
  
Phosphate-free Yeast Pulse Medium 20 g Select Peptone 
 10 g Yeast Extract 
 935 ml H20 
 10 ml 1 M MgSO4 
 10 ml aqueous NH4OH 
 remove precipitated phosphate by filtration 
 adjust to pH 5.8 
 autoclave 
 add 2 % Glucose 
 add 15 µCi/ml [32P]-ortho-phosphate 
 
 
4.7 Cell lines 
U2OS Human Osteosarcoma cell line 
2fTGH Human Fibrosarcoma cell line 
HeLa RPB1-#-Am (Rec-WT) with mutated RPB1 #-Am binding site 
Dicer1 +/+ MEF conditional knockout cells MEF clone 1C5 
Dicer1 +/+ MEF conditional knockout cells MEF clone 1C1 
Dicer1 -/- MEF conditional knockout cells MEF clone 1A11 
Dicer1 -/- MEF conditional knockout cells MEF clone 2G4 
 All MEF cells comprise floxed Dicer1 alleles, 
 conditionally depleted by Cre-recombinase, 
 and kindly provided by Dr. Vigo Heissmeyer 
 
 
4.8 Yeast strains 
Conditional knockout  strains  
CTK1 +/+ Strain  GAL1::CTK1-TAP 
CTK1 -/- Strain ∆ctk1::HIS3 
BUR2 +/+ Strain GAL1::BUR2-TAP 
BUR2 -/- Strain ∆bur2::HIS3 
 All strains are derived from W303 wt 
 (Mata/a; ura3-1; trp1-1; his3-11,15;  
 leu2-3,112; ade2-1; can1-100; GAL+) 
 kindly provided by Dr. Katja Strässer 
 
 
4.9 Oligonucleotides 
Name              Sequence (5’- to -3’) 
siATM (Zhu et al., 2004) UAGAGCUACAGAACGAAAGdTdT 
siATR (Zhu et al., 2004) AACCUCCGUGAUGUUGCUUGAdTdT 
siAurB (this thesis) GGAGAAUAGCAGUGGGACAdTdT 
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siCATS (this thesis) CUUGACCUUGAGCCUUCUAUUdTdT 
siCdk1 (L'Italien et al. 2006) GAUCAACUCUUCAGGAUUUdTdT 
siCdk2 (Zhang et al., 2004) AAGGUGGUGGCGCUUAAGAAAdTdT 
siCdk3 (this thesis) GAGCAAAGCACUAAGGAAUdTdT 
siCdk4 (Molenaar et al., 2008) AACCCACACAAGCGAAUCUCUdTdT 
siCdk5 (Meuer et al., 2007) GAGGAUCUUUCGACUGCUAdTdT 
siCdk6 (Molenaar et al., 2008) GUGAUUGGACUCCCAGGAGAAdTdT 
siCdk7 (Wohlbold et al., 2006) GCCUACAUGUUGAUGACUCdTdT 
siCdk8 (Tsutsui et al., 2008) CUACAAAGCCAAGAGGAAAdTdT 
siCdk9 (Pirngruber et al., 2009) GCAAGGGUAGUAUAUACCUGGUGUUdTdT 
siCdk9-55 (5’UTR/E1) (this thesis) CCGUCGGUUGCCAUGUCAAdTdT 
siCdk12 (Bartkowiak et al., 2010) Qiagen FlexiTube siRNA (SI00288442) 
siCdk13 (Bartkowiak et al., 2010) Qiagen FlexiTube siRNA (SI02621969) 
siCdk16 (this thesis) UGAGAUUGGCUUUGGGAAAdTdT 
siCHK1 (Shiromizu et al., 2006) AAGCGUGCCGUAGACUGUCCAdTdT 
siCK I (Chen et al., 2005) AAUCUCAGAAGGCCAGGCAUCdTdT 
siCK II (Rebholz et al., 2009) GUCCAUGAAAUAUUCCACCdTdT 
siDNA-PK (this thesis) CUGAAACACUAAAGAGAAAdTdT 
siGSK3 (this thesis) AGAAAGUAUUGCAGGACAAdTdT 
siJNK3 (this thesis) GCAAGAAACUGUUGAAUUAdTdT 
siLuc (GL2) (Eurofins/MWG) CGUACGCGGAAUACUUCGAdTdT 
siNLK (this thesis) GAGUGAUGGUGGAAGAUAAdTdT 
siNEK6 (this thesis) CCACGGAAGUCGAGAAUUAdTdT 
siNop56 (Knox et al., 2011) CAAUAUGAUCAUCCAGUCCAUdTdT 
siPes1 (Rohrmoser et al., 2007) AGGUCUUCCUGUCCAUCAAdTdT 
siPNK (Rasouli-Nia et al., 2004) AGAGAUGACGGACUCCUCUdTdT 
siPRK1 (Metzger et al., 2008) GAAAGUCCUAGAUCCACACGCAAUdTdT 
sihRIO2 (Zemp et al., 2009) GGAUCUUGGAUAUGUUUAAdTdT 
siSNK (Burns et al., 2003) AAGCGCUACUGCCGGGGCAAAdTdT 
siSRPK1 (this thesis) GGACAAAGCCCAAAGGAAAdTdT 
siTTBK1 (this thesis) GGUGAGAGGCAGUGGGCAAdTdT 
siVRK1 (Vega et al., 2004) GAAAGAGAGUCCAGAAGUAdTdT 
 
 
4.10 Probes 
Name   Sequence (5’- to -3’) 
mRNA (Homo sapiens) 
GAPDH   CCAGCAGTGAGGGTCTCTCTCTTCCTCTTG 
c-Myc   GGAGGCTGCTGGTTTTCCACTACCCGAAAAAAATCCA 
 
rRNA (Homo sapiens) 
5’ETS (1)  CGGAGGCCCAACCTCTCCGACGACAGGTCGCCAGAGGACAGCGTGTCAGC  
5’ETS (2)  CGGTACCCCCAAGGCACGCCTCTCAGATCGCTAGAGAAGGCTTTTCTC 
ITS-1 (3)  AGCGCGGACACCACCCCACAGGCGCCCGGGGGTTCC 
ITS-1 (4)  TCCCGACGACGCACCGGGAGGAGGCCCTTCCTGGCGCGGCACGTCCCC 
ITS-2 (5)  CTCTCTTTCCCTCTCCGTCTTCCGGCGGCGGCGCCGCCCTCCCCGTCT 
ITS-2 (6)  TACGCGCGGGGAGGGCGAGGAGGACGG CGGGGCCTCGGAGGA 
3’ETS (7)  AACGCGCACGCCCGCCGGGCCCCCCGCACGCAC 
3’ETS (8)  CTCCCAAACCACGCTCCCCGGACCCCGTCCCGGCCCGGAG 
3’ETS (9)  ACG GGG AGG AGG CGG GAA CCGAAGAAGCGGGGCGGCCGACCGGGGTC 
3’ETS (10)  TCGACCCGTGCGGAGGAGCGAGGAGGAAGGACG 
3’ETS (11)  GCTAAGTCCGGAGCTCGCGGGCGGCAGCTGGTC 
3’ETS (12)  GAGAGGGAGTTCCGCGTGGTCCCAGCTCCACCGCG 
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3’ETS (13)  CGCGGACGCAAACTCGCGGTGGGGCTGAA 
3’ETS (14)  GCGAGAGGGCGAGAGCGACAGAGAGAGAGAG 
 
rRNA (Mus musculus) 
5.8S (A)  CTGCAATTCACATTAATTCTCGCAGCTAGCTGCGTTCTTCATCGA 
28S (B)  AGGTCGCGGTCAGAAAGGGGGGACACGCGCCCAGCCGCGGGAAGA 
3’ETS (C)  ACCGCCCCCGTGACGCCCGGGCGACGACACGGTCGCGTGCGAGCG 
3’ETS (D)  ACGGACGCGCCGAGGATGGGGATCCCACCGTCGGTCACCGGCCCG 
 
snoRNA (Homo sapiens) 
SNORA8 (ACA8)  CCTAGCAGGTGTAAACTGCTGAGTGCAGATACCATG 
SNORA21 (ACA21) CGATGTTTTCACTCTCCCCTTTCTTGACGGCTCAATAG 
SNORA38B (ACA38B) AAGCTGGCCCCAGATTTCTCCAAGTCCACATTTC 
SNORA73A (U17A, E1) TTCCAACGTTGTGGAAAGGGACTTGTACATCATGG 
SNORD3 (U3)  CTTCACGCTCAGGAGAAAACGCTACCTCTCTTCCT 
SNORD14A (U14A) CTTTCTGGTGGAAACTGCGAATGTTGGAAAACCATCATCAC  
SNORD14B (U14B) ATTTCTGGTGGAAACTGCGAATGTCTGGCAACCAATCATCATAG 
SNORD22 (U22)  ACAGGCTCTGGGACTAGGACAGAGAGTAAGACATGT 
SNORD24 (U24)  GCATCAGCGATCTTGGTGGTTTAAAATGTCATCACCATCTC 
SNORD76 (U76)  TCAGTTAAGATAATGGTGGTTAAGATCCTCATCATTCTAGCACTCAAGA  
SNORD117 (U83)  GCCATCAGTCATGGGTGATAGATAAGAGTCGTCCT 
SNORD118 (U8)  CAAGTCCTGATTACGCAGAGACGTTAATCACGTTTCATGC 
 
 
4.11 Primers 
Name   Sequence (5’- to -3’) 
mRNA (Homo sapiens) 
Nop56   FWD: AATTCCACAGCATCGTTCG 
 REV: GCGGAGGTCCTCATGAAC 
 
 
4.12 Antibodies 
Primary Antibodies  source   clone  species  usage 
Human anti-CATS   Dr. E. Kremmer  2C4  rat  WB 1:10 
Human anti-Cdk2   Santa Cruz (sc-163) M2  rabbit  WB 1:2000 
Human anti-Cdk4   Santa Cruz (sc-260) C22  rabbit  WB 1:5000 
Human anti-Cdk5   Santa Cruz (sc-173) C8  rabbit  WB 1:5000 
Human anti-Cdk6   Santa Cruz (sc-177) C21  rabbit  WB 1:2000 
Human anti-Cdk7   Santa Cruz (sc-529) C19  mouse  WB 1:10000 
Human anti-Cdk8  Santa Cruz (sc-13155) D-9  mouse  WB 1:1000 
Human anti-Cdk9   Santa Cruz (sc-484) C20  rabbit  WB/IF 1:2000 
Human anti-c-Myc   Dr. E. Kremmer  9E10  mouse  WB 1:10 
Human anti-NPM1 (B23)  Sigma (B0556)  FC82291  mouse  IF 1:2000 
Human anti-p53    Santa Cruz (sc-126) DO-1  mouse  WB 1:2000 
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Human anti-Pes1   Dr. E. Kremmer  8E9  rat  WB 1:10 
Human anti-#-Tubulin   Sigma (TG199)  DM1A  mouse  WB 1:10000 
Mouse anti-Dicer1   Dr. V. Heissmeyer polyclonal rabbit  WB 1:100 
 
Secondary Antibodies  source     species  usage 
Cy3-AffiniPure Goat   Jackson InnunoRes.   mouse  IF 1:300 
Cy3-AffiniPure Goat   Jackson InnunoRes.   rabbit  IF 1:300 
HRP-conjugated #-IgG  Promega    rabbit  WB 1:2500 
HRP-conjugated #-IgG  Promega    mouse  WB 1:5000 
HRP-conjugated #-IgG  Promega    rat  WB 1:5000 
 
WB:  Western blot 
IF:  Immunofluorescence 
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5. METHODS 
 
 
 
 
 
5.1 Cell culture  
 
5.1.1 Cell thawing 
Deep frozen cell stock aliquots (-80°C) were thawed in a 37°C water bath, 
resuspended in pre-warmed thaw medium and centrifuged (4 min, 1200 rpm). The 
cell pellet was washed twice with 1 x PBS and centrifuged (4 min, 1200 rpm). The cell 
pellet was resuspended in thaw medium and cells were plated and cultured for 24 
hours at 37°C, 8 % CO2. Subsequently, thaw medium was replaced by DMEM 
complete (adherent cells) or RPMI complete (suspension cells).   
 
5.1.2 Cell cultivation 
Adherent cells were cultured at 37°C and 8 % CO2 (suspension cells at 5 % 
CO2). A running culture was split and diluted 1:10 every two to three days. 
Therefore, adherent cells were washed with 1 x PBS, trypsinated for 5 min, and 
resuspended in DMEM complete. Suspension cells were split 1:10 by discarding 90 % 
of the culture medium every two to three days.  
 
5.1.3 Cell counting 
Cell number was determined in a Fuchs-Rosenthal chamber. Trypsinated and 
resuspended adherent cells were mixed 1:1 with 0.4 % Tryphan Blue (suspension 
cells were directly mixed 1:1). Bright staining, living cells were counted under a 
microscope. The cell number in 1 ml medium is calculated by multiplication of the 
median number of cells from four squares with factor 104. This factor transfers the 
volume of one square (= 0.1 mm3) into 1 ml. 
 
5.1.4 Proliferation assay 
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Cell proliferation was measured indirectly by electric impedance detection 
using the Roche xCELLigence device. 3000 cells were plated on an electronic plate (E-
plate), which is capable of measuring electric impedance in real time by electrodes in 
direct contact with adherent cells. Impedance increases with the area on electrodes, 
which is covered by proliferating cells and is termed ‘cell index’. After plating, cells 
were cultured over night, transfected, and cultured for additional three days. In total, 
cells were measured for 100 hours in 15 min intervals. 
 
 
5.2 Cell manipulation 
 
5.2.1 Cell selection 
Recombinant HeLa cells, harboring an #-amanitin (#-Am) resistant RNA 
polymerase II (RNAP II) were created as described elsewhere (Bartolomei and 
Corden 1987; Meininghaus et al., 2000). Pre-selected HeLa cells, which express an #-
Am-resistant recombinant wild type RNAP II (Rec-WT HeLa), were enriched and 
protected from revertants by cultivating them in 2 µg/ml #-Am. 
Recombinant Dicer1 conditional knockout mouse embryonic fibroblast (MEFs) 
cells were created as described elsewhere (Bernstein et al., 2003). Conditional Dicer1 
double knockout was induced by addition of Cre-recombinase to MEF cells. A stable 
Dicer1 knockout cell line was obtained by single cell cloning. Conditional Dicer1 
MEFs were a generous gift from Dr. Vigo Heissmeyer.  
 
5.2.2 Cell transfection 
Adherent cells were plated in six-well plates (90000 cells/well) and cultured 
for 24 hours in DMEM complete. Subsequently, cells were washed with 1 x PBS and 
pre-incubated with OptiMEM transfection medium. For transient transfection of 100 
nM short interfering (si)RNA, both oligofectamine transfection reagent and siRNA 
(100 µM) were diluted in OptiMEM (3 µl Oligofectamine in 150 µl OptiMEM; 0.9 µl 
siRNA in 150 µl OptiMEM) and incubated separately at room temperature (RT) for 5 
min. Both dilutions were united and incubated at RT for 20 min. Subsequently, 600 µl 
OptiMEM were added to the mixture, resulting in a 900 µl transfection sample. Pre-
incubated cells were aspirated and incubated with the transfection sample for 6 
hours. Cells were aspirated and cultured in DMEM complete. Transient transfection 
was repeated after 24 hours.  
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5.2.3 Drug treatment 
Drugs were stored at -20°C as stock solutions dissolved in appropriate solvent 
(DMSO, H2O, or EtOH). For treatment of cells, drugs stocks were freshly pre-diluted 
in 1 x PBS or DMSO. Pre-dilutions were added to culture medium for 6 hours or less.  
 
5.2.4 [32P]-ortho-phosphate metabolic in vivo labelling 
200000 adherent cells were metabolically labelled with radioactive [32P]-ortho-
phosphate (32P). Cells were stressed with 100 nM siRNA (2 x 6 hours) or drug 
treatment (2 hours) prior to labelling. Subsequently, DMEM was replaced by 
depletion medium for 1 hour to deplete endogenous phosphate pool. In case of drug 
treatment, depletion medium also was supplemented with the drug. Depletion 
medium was replaced by pulse medium containing 15 µCi/ml 32P for 1 hour in 
absence of the drug (pulse). Pulse medium was replaced by DMEM complete for up 
to 3 hours in presence of the drug (chase). Culture medium was removed and cells 
were lyzed in 350 µl RLT lysis buffer. Lysates were shredded by loading to a DNA 
removal column and centrifugation (3 min, 13000 rpm). Lysates were frozen at -20°C. 
Medium change steps in metabolic labelling of suspension cells required pelleting (4 
min, 1200 rpm) prior to medium change.  
 
5.2.5 Cell freezing 
A confluent adherent cell culture was washed with 1 x PBS, trypsinated, and 
resuspended in DMEM complete. A suspension culture aliquot was taken directly 
without trypsination. Cells were pelleted (4 min, 1200 rpm), washed in 1 x PBS, and 
pelleted again (4 min, 1200 rpm). Cell pellets were resuspended in freeze medium 
and deep frozen in Cryovails at -80°C. 
 
 
5.3 Yeast culture 
 
5.3.1 Recombinant yeast strains 
Conditional yeast Ctk1 or Bur1/2 knockout strains were created as described 
elsewhere (Röther and Strässer, 2007). In brief, endogenous CTK1 or BUR2 genes 
were deleted in yeast wild type strain W303 (Mata/a; ura3-1; trp1-1; his3-11, 15; leu2-
3, 112; ade2-1; can1-100; GAL+) and replaced by stable transformation with 
conditional expression plasmids coding for recombinant TAP-tagged Ctk1 or Bur2 
(CTK1-TAP or BUR2-TAP). Expression of Ctk1-TAP and Bur2-TAP is under control 
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of a galactose inducible promoter. Conditional knockout was induced by medium 
switch from YPG to YPD. Yeast growth was monitored by optical density 
measurement at 600 nm. Conditional knockout strains were a generous gift from Dr. 
Katja Strässer. 
 
5.3.2 [32P]-ortho-phosphate metabolic yeast in vivo labelling 
Yeast was cultured over night in YPD to induce knockout for 18 hours. Over night 
cultures were diluted to OD600= 0.15 in YPD-P and cultured for additional 6 hours to 
deplete the endogenous phosphate pool. Phosphate-free YPD-P was obtained by 
alkalic phosphate precipitation with 10 mM MgSO4 and 1 % aqueous NH4OH (Rubin, 
1974). Yeast optical density was kept below OD600= 1.5. Exponentially growing yeast 
was metabolically labelled with 15 µCi/ml 32P for 5 min (pulse). Subsequently, 
labelled yeast was harvested (30 min, 3000 rpm) and washed in 400 µl TE. Yeast was 
again harvested (30 sec, 3000 rpm) and resuspended in 200 µl S-buffer, containing 1 
M Sorbitol. For spheroblasting, 250 µl S-buffer supplemented with 20 mg/ml 
Zymolyase 20T and 2 µl $-ME/ml was added to the yeast suspension. Yeast cell wall 
was digested at 30° for 3 min (spheroblasting). Spheroblasts were harvested (30 sec, 
3000 rpm), and resuspended in S-Buffer. Yeast spheroblasts were centrifuged (1 min, 
300 rpm), S-Buffer was completely removed, and the spheroblast pellet was 
resuspended in 350 µl RLT lysis buffer. Spheroblasts were vortexed in RLT lysis 
buffer for 5 min. Lysates were frozen at -20°C. 
 
 
5.4 DNA analytics 
 
5.4.1 Complementary DNA (cDNA) synthesis 
Human U2OS cDNA was synthesized as a reverse transcribed, random primed 
library derived from 2 µg total RNA, which was purified with the PeqGOLD total 
RNA kit (see RNA analytics part for details). 
 
20 µl reverse transcription reaction (one sample): 
Random Hexamer Primer (0.2 µg/µl)  1 µl 
Total RNA (2 µg)    x µl 
dNTPs (10 mM each)    1 µl 
ddH2O     ad 12 µl 
mix, incubate at 65°C, 5 min, add: 
5 x First-Strand-Buffer    4 µl 
0.1 M $-Mercaptoethanol   2 µl 
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RNAsin RNAse-inhibitor   1 µl 
mix, incubate at RT, 2 min, add 
Superscript Reverse Transcriptase (200 units) 1 µl 
mix, incubate, at RT, 10 min  
incubate at 42°C, 50 min (reverse transcription) 
incubate at 70°C, 15 min (inactivation) 
freeze at -20°C 
 
5.4.2 Quantitative real-time polymerase chain reaction (qPCR) 
Specific primers for qPCR of random primed human cDNA were designed with the 
Roche universal probe library. The cDNA levels were measured with the Roche Light 
Cycler FastStart DNA Master SYBR Green I kit and calculated by comparison of Cp-
values. Relative cDNA levels were calculated by the ∆∆Cp-method (e.g. ∆Cp = 3.98, 
i.e. 1/23.98 = 0.063 = 6 % cDNA compared to control situation).  
 
10 µl reaction mixture (one sample): 
  H2O (PCR grade)    4.2 µl 
  DMSO      0.5 µl 
  MgCl2      0.8 µl 
  Roche-Mix (a+b)    1 µl 
  cDNA (1:20 dilution)    2.5 µl 
  Primer-Mix (5 µM FWD+REV)   1 µl 
 
PCR program: 
Step    Cycles  Conditions 
Denaturation   1  95°C, 10 min 
Amplification     95°C, 1 sec 
    35  62°C, 10 sec 
      72°C, 8 sec 
Melting   1  70° to 97°, 20°/sec ramp rate 
Cooling   1  40°, ∞ 
 
Primer specificity was monitored in cDNA dilution series experiments by measuring 
Cp-values of three different cDNA dilutions. The melting temperature of the qPCR 
product was measured. The predicted qPCR product size was confirmed by agarose-
gel electrophoresis. 
 
5.4.3 DNA agarose-gel electrophoresis 
For a 1.5 % DNA agarose-gel, 6 g agarose was boiled in 400 ml 1 x TAE buffer. 3.75 
µl/100 ml Ethidium Bromide (EtBr, stock: 10 mg/µl) was added after cooling of the 
gel to 65°C. PCR products were mixed with 10 x DNA loading dye and loaded on the 
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gel. The gel was run with a 1 kilobase DNA ladder in 1 x TAE buffer (100 V, 3 hours). 
A gel photo was taken under UV light. 
 
 
5.5 RNA analytics 
 
5.5.1 RNA isolation and concentration detection 
The PeqGOLD total RNA kit was used for total RNA isolation from human cells and 
yeast. Deep frozen lysates were thawed and RLT lysis buffer was mixed with an 
equal amount (350 µl) of 70 % EtOH. Lysates were loaded on an RNA binding 
column and centrifuged (30 sec, 13000 rpm). The column was washed once with 600 
µl wash buffer I and twice with 500 µl wash buffer II (30 sec, 13000 rpm). The column 
was dried by empty centrifugation at 14000 rpm for 3 min. RNA was eluted in 35 µl 
DEPC-H2O. RNA concentration was measured with the Nanodrop System. 
 
5.5.2 RNA agarose-gel electrophoresis 
A 1.25 % formaldehyde agarose-gel was used to analyze total RNA. 4.5 g agarose 
was boiled in 300 ml DEPC-H2O. After cooling to 65°C, 40 ml 10 x MOPS buffer and 
67 ml 37 % Formaldehyde were added. Equal amounts of total RNA samples (1 µg 
for detection of metabolic label, 8 µg for Northern blot experiments) were prepared 
by mixing RNA with a 2 x RNA loading dye (50 % v/v) and DEPC-H2O to adjust the 
volume. RNA samples were incubated at 55°C for 12 min prior to loading. The gel 
was run in 1 x MOPS buffer at 100 V for 3-6 hours. A gel photo was taken under UV 
light. 
 
5.5.3 Autoradiography 
Metabolically labelled RNA was analyzed by autoradiography after separation by 
RNA agarose-gel electrophoresis. The gel was put in a gel dryer on top of a 
Whatman paper and covered with a PVDC foil. A vacuum pump was used to dry the 
gel for 5 hours at 80°C. The dried gel was put into a detection cassette and covered 
with an autoradiography detection film, which was exposed at -80°C for 4 hours. A 
developing machine was used to visualize signals. Dried gels were exposed to a pre-
erased BAS Imaging Plate for 5 min for quantitation of metabolically labelled RNA. 
rRNA signals were read out with a PhosphorImager and quantified by AIDA 
software.  
 
Methods 
-87- 
5.5.4 4sU-tagging 
1500000 cells were cultured with 10 µM 4-thiouridine (4sU) for various time points. 
Cells were lyzed and total RNA was isolated as described above. 50 µg total RNA 
was incubated with 1 mg/ml Biotin-HPDP (2 µl/µg RNA) in 10 x biotinylation buffer 
(1 µl/µg RNA) for 1.5 hours with rotation at room temperature in a final volume of 
500 µl. Biotin-HPDP is pyridyldithiol-activated and allows thiol-specific biotinylation 
of 4sU-tagged RNA by the formation of disulfide bonds with the -SH group of 4sU. 
An equal volume of chloroform was added, mixed, and incubated with biotinylated 
RNA for 3 min. The mixture was separated by centrifugation (5 min, 16000 rpm) in 
pre-spun Phase Trap Gel Heavy Tubes. For RNA precipitation and removal of 
unincorporated Biotin-HPDP, an 1/10 volume 5 M NaCl and an equal volume of 
absolute isopropanol were added to the aqueous phase and centrifuged (20 min, 
16000 rpm). The pellet was washed in an equal volume of 75 % ethanol and 
centrifuged (10 min, 16000 rpm). RNA was resuspended in 100 µl RNAse-free H2O. 
For separation of 4sU-tagged and untagged RNA, RNA was first heated to 65°C for 
10 min and cooled on ice for 5 min. Subsequently, RNA was incubated with 75 µl 
Streptavidin-coated magnetic beads (Miltenyi) for 15 min with rotation. The reaction 
volume was applied to µMACs columns (Miltenyi), which were placed in an 
OctoMACS Seperator magnetic stand, and equilibrated with 900 µl 1 x µMACS 
washing buffer. The columns were washed three times with 800 µl 65°C warm 1 x 
µMACS washing buffer and two times with 800 µl cold 1 x µMACS washing buffer. 
Nascent 4sU-Biotin-Streptavidin-tagged RNA was eluted in 700 µl RLT lysis buffer 
with twice 100 µl DDT (100 mM) by reducing 4sU-S-S-Biotin disulfide bonds. 
Nascent, 4sU-tagged RNA was recovered with the PeqGOLD total RNA kit as 
described above. Untagged, unbound RNA was recovered from the flow through 
and first wash of µMACS columns by isopropanol/ethanol precipitation as described 
above. RNA fractions were analyzed by RNA agarose-gel electrophoresis.  
 
5.5.5 Northern blot hybridization 
Unlabelled RNA was analyzed by Northern blot hybridization after separation by 
RNA agarose-gel electrophoresis. RNA was transferred to a Hybond N+ nylon 
membrane by vertical transfer over night in 10 x SSC buffer and cross-linked to the 
membrane with UV light (120 mJoule, 30 sec). Specific probes were used for 
detection of unlabelled RNA. Probes were end-labelled with !-32P-
Desoxyadenosinetriphosphate (!-32P-dATP) and T4 Polynucleotide Kinase (PNK) at 
37°C for 1 hour.  
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20 µl reaction mixture (one sample):  
DEPC-H2O    2 µl 
DNA-probe (1 µM)   1 µl 
PNK buffer (10 x)   1 µl 
PNK (10000 units)   1 µl 
!-32P-dATP (6000 µCi/mmol)  5 µl 
 
End-labelled probes were mixed with 40 µl 1 x TE buffer, purified by Micro Spin 
columns (2 min, 3500 rpm), and denaturated at 90°C for 2 min. For hybridization, 
purified probes were added to hybridization tubes containing RNA cross-linked on 
membranes, which were pre-incubated with 15 ml 65°C warm Church buffer for 1 
hour. The probes were hybridized to membranes at 65°C over night. Membranes 
were washed 10 min each with 20 ml 2 x SSC wash buffer and 0.5 x SSC wash buffer. 
Membranes were put into a detection cassette, covered with PVDC foil, and signals 
were detected and quantified as described in part Autoradiography. 
 
 
5.6 Protein analytics 
 
5.6.1 Immunofluorescence microscopy 
80000 cells were plated on sterile glass slides. Cells were washed with 1 x PBS and 
fixed with 37°C pre-warmed 2 % para-formaldehyde (PFA) for 2 min. PFA was 
removed and inactivated by washing three times with 1 x PBS. Fixed cells were 
permeabilized with 0.04 % PBST for 7 min and incubated with FBS blocking solution 
for 2 hours. Cells were incubated with primary antibodies, diluted in FBS antibody 
solution, specifically recognizing endogenous proteins, in a wet chamber at 4°C over 
night. Primary antibodies were washed three times with 0.04 % PBST for 3 min. Cell 
were incubated with fluorochrome-conjugated secondary antibodies, diluted in FBS 
antibody solution, specifically recognizing primary antibodies, for 2 hours at RT. 
Afterwards, secondary antibodies were washed three times with 0.04 % PBST for 3 
min. Cells were incubated with DAPI staining solution for 2 min and washed twice 
with 1 x PBS. Cells were then mounted in Vecta Shield medium and protected from 
drying with nail polish. A Zeiss Axiovert 200M IF microscope (63 x Ph3) was used 
for analysis. Pictures were taken at constant acquisition times with a CCD camera 
and enhanced for contrast and staining by Openlab Software. See also part Antibodies 
for details. 
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5.6.2 Western blot hybridization 
200000 cells were plated for Western blot analysis. Cells were washed in 1 x PBS and 
lyzed in 2 x Lämmli buffer. Lysates were transferred to 1.5 ml reaction tubes and 
boiled at 95°C for 3 min. Lysates were sonicated (50 % duty cycle, output level: 5, 
shots: 4). 10 µl lysate samples were loaded and separated on a denaturating SDS-
polyacrylamide gel with a 10.5 % separating gel and a 4 % stacking gel in 1 x SDS 
running buffer (SDS-PAGE, 30 mA for 1.5 hours). 3.5 µl of a pre-stained protein 
ladder was used as a running marker. The gel was transferred to a nitrocellulose 
membrane by semi-dry blotting in 1 x transfer buffer (450 mA, 1.5 hours). The 
membrane was blocked in milk powder solution (1 hour at RT) and incubated with 
specific primary antibodies, diluted in antibody stock solution, on a roller mixer at 
4°C over night. Primary antibodies were removed and membranes were washed 
three times with 1 x TBST for 5 min. Membranes were incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies, specifically recognizing primary 
antibodies. Secondary antibodies were diluted in milk powder solution and 
hybridized to membranes for 1.5 hours at RT. Membranes were washed three times 
with 1 x TBST for 5 min and briefly poured in H2O. An enhanced chemiluminescence 
(ECL) kit was used for signal detection. Detection reagents were mixed (1:1) and 
incubated with membranes for 2 min. Membranes were put into a detection cassette, 
a film was exposed and signals were detected with a developing machine. Signals 
were quantified by AIDA and ImageJ software. See also part Antibodies for details. 
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